Publications

Publications published since 2000 from OUS - Department of Cancer Genetics

1087 publications found (only first 1000 shown)

Publications 2024

  1. Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S (2024)
    Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
    Cell Rep Med, 5 (5), 101521
    DOI 10.1016/j.xcrm.2024.101521, PubMed 38653245
  2. Aittokallio T, Fang EF (2024)
    Editorial overview-Artificial intelligence methodologies in structural biology: Bridging the gap to medical applications
    Curr Opin Struct Biol, 87, 102862
    DOI 10.1016/j.sbi.2024.102862, PubMed 38870638
  3. Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
    Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
    Mol Oncol (in press)
    DOI 10.1002/1878-0261.13675, PubMed 38978352
  4. Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
    Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
    J Immunother Cancer, 12 (1)
    DOI 10.1136/jitc-2023-007990, PubMed 38242720
  5. Ankill J, Zhao Z, Tekpli X, Kure EH, Kristensen VN, Mathelier A, Fleischer T (2024)
    Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation
    PLoS Comput Biol, 20 (11), e1012565
    DOI 10.1371/journal.pcbi.1012565, PubMed 39556603
  6. Bai B, Wise JF, Vodák D, Nakken S, Sharma A, Blaker YN, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence MS, Myklebost O, Kimby E, Pan-Hammarström Q, Steen CB, Meza-Zepeda LA, Beiske K, Smeland EB, Hovig E, Lingjærde OC, Holte H, Myklebust JH (2024)
    Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
    Blood Cancer J, 14 (1), 147
    DOI 10.1038/s41408-024-01124-5, PubMed 39191762
  7. Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
    Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
    Acta Oncol, 63, 487-490
    DOI 10.2340/1651-226X.2024.24954, PubMed 38910311
  8. Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
    Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
    Int J Cancer, 155 (2), 282-297
    DOI 10.1002/ijc.34915, PubMed 38489486
  9. Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, Elmadani M, Hynninen J, Hautaniemi S, Aittokallio T, Wennerberg K (2024)
    A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells
    Sci Adv, 10 (21), eadj1564
    DOI 10.1126/sciadv.adj1564, PubMed 38781347
  10. Chen L, Wang X, Xie N, Zhang Z, Xu X, Xue M, Yang Y, Liu L, Su L, Bjaanæs M, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Zhang R (2024)
    A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
    Mol Oncol (in press)
    DOI 10.1002/1878-0261.13766, PubMed 39630602
  11. Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
    Gynecol Oncol, 189, 138-145
    DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895
  12. Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
    Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
    Virchows Arch (in press)
    DOI 10.1007/s00428-024-03912-7, PubMed 39235515
  13. Demir MF, Lin YH, Costa Cruz PH, Tajima M, Honjo T, Müller E (2024)
    Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity
    Front Immunol, 15, 1479502
    DOI 10.3389/fimmu.2024.1479502, PubMed 39497822
  14. Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Zecic N, Moe JO, Lund-Iversen M, Brustugun OT (2024)
    Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer
    Clin Exp Med, 24 (1), 10
    DOI 10.1007/s10238-023-01273-0, PubMed 38240952
  15. Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium (2024)
    High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
    J Intern Med, 295 (6), 785-803
    DOI 10.1111/joim.13785, PubMed 38698538
  16. Fei L, Zhang K, Hautaniemi S, Sahu B (2024)
    Protocol to identify defined reprogramming factor expression using a factor-indexing single-nuclei multiome sequencing approach
    STAR Protoc, 5 (3), 103148
    DOI 10.1016/j.xpro.2024.103148, PubMed 38909361
  17. Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024)
    Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    ESMO Open, 9 (6), 103464
    DOI 10.1016/j.esmoop.2024.103464, PubMed 38833971
  18. Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
    An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
    Mol Oncol, 18 (8), 2042-2059
    DOI 10.1002/1878-0261.13656, PubMed 38671580
  19. Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S (2024)
    Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
    J Med Imaging Radiat Sci, 55 (2), 221-231
    DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174
  20. Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK (2024)
    Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
    Br J Cancer (in press)
    DOI 10.1038/s41416-024-02895-1, PubMed 39489879
  21. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
    [Raising the quality of cancer treatment]
    Tidsskr Nor Laegeforen, 144 (1)
    DOI 10.4045/tidsskr.23.0740, PubMed 38258713
  22. Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
    UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    Eur J Cancer, 202, 113973
    DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
  23. Ianevski A, Kushnir A, Nader K, Miihkinen M, Xhaard H, Aittokallio T, Tanoli Z (2024)
    RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies
    Brief Bioinform, 25 (4)
    DOI 10.1093/bib/bbae328, PubMed 38980370
  24. Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T (2024)
    Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
    Nat Commun, 15 (1), 8579
    DOI 10.1038/s41467-024-52980-5, PubMed 39362905
  25. Karttunen K, Patel D, Sahu B (2024)
    Transposable elements as drivers of dedifferentiation: Connections between enhancers in embryonic stem cells, placenta, and cancer
    Bioessays, 46 (10), e2400059
    DOI 10.1002/bies.202400059, PubMed 39073128
  26. Mahon P, Chatzitheofilou I, Dekker A, Fernández X, Hall G, Helland A, Traverso A, Van Marcke C, Vehreschild J, Ciliberto G, Tonon G (2024)
    A federated learning system for precision oncology in Europe: DigiONE
    Nat Med, 30 (2), 334-337
    DOI 10.1038/s41591-023-02715-8, PubMed 38195748
  27. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A (2024)
    Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
    Acta Oncol, 63, 213-219
    DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
  28. Moragas N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, López-Plana A, Bergholtz H, Noguera-Castells A, Del Burgo PJ, Chen X, Sorlie T, Gascón P, Bragado P, Bissell M, Carbó N, Fuster G (2024)
    The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma
    Breast Cancer Res, 26 (1), 122
    DOI 10.1186/s13058-024-01871-0, PubMed 39138514
  29. Nader K, Tasci M, Ianevski A, Erickson A, Verschuren EW, Aittokallio T, Miihkinen M (2024)
    ScType enables fast and accurate cell type identification from spatial transcriptomics data
    Bioinformatics, 40 (7)
    DOI 10.1093/bioinformatics/btae426, PubMed 38936341
  30. Niehusmann P, Leske H, Nygaard V, Russnes HG, Zhao S, Latysheva A, Straume Wiig U, Stankuniene B, Ulvmoen A (2024)
    Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications
    Acta Oncol, 63, 392-394
    DOI 10.2340/1651-226X.2024.31720, PubMed 38779936
  31. Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
    Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
    Front Oncol, 14, 1412716
    DOI 10.3389/fonc.2024.1412716, PubMed 39148905
  32. Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
    Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
    ESMO Open, 9 (6), 103475
    DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
  33. Otterlei Fjørtoft M, Huse K, Rye IH (2024)
    The Tumor Immune Microenvironment in Breast Cancer Progression
    Acta Oncol, 63, 359-367
    DOI 10.2340/1651-226X.2024.33008, PubMed 38779867
  34. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
    IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
    Acta Oncol, 63, 379-384
    DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
  35. Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L et al. (2024)
    Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
    Hemasphere, 8 (12), e70001
    DOI 10.1002/hem3.70001, PubMed 39619245
  36. Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen CJ, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P et al. (2024)
    Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023
    Mol Oncol, 18 (2), 245-279
    DOI 10.1002/1878-0261.13575, PubMed 38135904
  37. Schulman A, Rousu J, Aittokallio T, Tanoli Z (2024)
    Attention-based approach to predict drug-target interactions across seven target superfamilies
    Bioinformatics, 40 (8)
    DOI 10.1093/bioinformatics/btae496, PubMed 39115379
  38. Shahrouzi P, Forouz F, Mathelier A, Kristensen VN, Duijf PHG (2024)
    Copy number alterations: a catastrophic orchestration of the breast cancer genome
    Trends Mol Med, 30 (8), 750-764
    DOI 10.1016/j.molmed.2024.04.017, PubMed 38772764
  39. Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
    Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
    BMC Cancer, 24 (1), 555
    DOI 10.1186/s12885-024-12320-8, PubMed 38702616
  40. Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C et al. (2024)
    Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
    J Clin Invest, 134 (8)
    DOI 10.1172/JCI168536, PubMed 38618957
  41. Tanoli Z, Schulman A, Aittokallio T (2024)
    Validation guidelines for drug-target prediction methods
    Expert Opin Drug Discov, 1-15 (in press)
    DOI 10.1080/17460441.2024.2430955, PubMed 39568436
  42. Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
    PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
    Acta Oncol, 63, 385-391
    DOI 10.2340/1651-226X.2024.34791, PubMed 38779910
  43. Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
    Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
    Eur J Nucl Med Mol Imaging (in press)
    DOI 10.1007/s00259-024-06853-0, PubMed 39133306
  44. Tomasova K, Seborova K, Kroupa M, Horak J, Kavec M, Vodickova L, Rob L, Hruda M, Mrhalova M, Bartakova A, Bouda J, Fleischer T, Kristensen VN, Vodicka P, Vaclavikova R (2024)
    Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma
    Heliyon, 10 (13), e33525
    DOI 10.1016/j.heliyon.2024.e33525, PubMed 39050459
  45. Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
    Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
    Mol Oncol (in press)
    DOI 10.1002/1878-0261.13760, PubMed 39545921
  46. van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J (2024)
    ESMO Recommendations on clinical reporting of genomic test results for solid cancers
    Ann Oncol, 35 (11), 954-967
    DOI 10.1016/j.annonc.2024.06.018, PubMed 39112111
  47. von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen D et al. (2024)
    Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
    Blood, 144 (15), 1595-1610
    DOI 10.1182/blood.2023022884, PubMed 38941598
  48. Zhao Z, Zobolas J, Zucknick M, Aittokallio T (2024)
    Tutorial on survival modeling with applications to omics data
    Bioinformatics, 40 (3)
    DOI 10.1093/bioinformatics/btae132, PubMed 38445722

Publications 2023

  1. Athanasiadis P, Ravikumar B, Elliott RJR, Dawson JC, Carragher NO, Clemons PA, Johanssen T, Ebner D, Aittokallio T (2023)
    Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
    iScience, 26 (7), 107209
    DOI 10.1016/j.isci.2023.107209, PubMed 37485377
  2. Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
    Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
    Acta Oncol, 62 (12), 1642-1648
    DOI 10.1080/0284186X.2023.2264484, PubMed 37801361
  3. Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T (2023)
    Robust scoring of selective drug responses for patient-tailored therapy selection
    Nat Protoc, 19 (1), 60-82
    DOI 10.1038/s41596-023-00903-x, PubMed 37996540
  4. Daniel P, Balušíková K, Václavíková R, Šeborová K, Ransdorfová Š, Valeriánová M, Wei L, Jelínek M, Tlapáková T, Fleischer T, Kristensen VN, Souček P, Ojima I, Kovář J (2023)
    ABCB1 Amplicon Contains Cyclic AMP Response Element-Driven TRIP6 Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines
    Genes (Basel), 14 (2)
    DOI 10.3390/genes14020296, PubMed 36833223
  5. Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkönen M, von Schantz-Fant С, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J (2023)
    PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells
    Mol Oncol, 17 (9), 1803-1820
    DOI 10.1002/1878-0261.13488, PubMed 37458534
  6. Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Moe JO, Eide IJZ, Lund-Iversen M, Brustugun OT (2023)
    "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer"
    Diagn Pathol, 18 (1), 70
    DOI 10.1186/s13000-023-01357-1, PubMed 37237384
  7. Figlioli G, Billaud A, Wang Q, Bolla MK, Dennis J, Lush M, Kvist A, Adank MA, Ahearn TU, Antonenkova NN, Auvinen P, Behrens S, Bermisheva M, Bogdanova NV, Bojesen SE, Bonanni B, Brüning T, Camp NJ, Campbell A, Castelao JE, Cessna MH, Nbcs Collaborators, Czene K, Devilee P, Dörk T et al. (2023)
    Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases
    Cancers (Basel), 15 (13)
    DOI 10.3390/cancers15133313, PubMed 37444426
  8. Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H (2023)
    Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature
    Curr Oncol, 30 (11), 10007-10018
    DOI 10.3390/curroncol30110727, PubMed 37999147
  9. Halkola AS, Joki K, Mirtti T, Mäkelä MM, Aittokallio T, Laajala TD (2023)
    OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer
    PLoS Comput Biol, 19 (3), e1010333
    DOI 10.1371/journal.pcbi.1010333, PubMed 36897911
  10. Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
    Liver X receptors induce antiproliferative effects in basal-like breast cancer
    Mol Oncol, 17 (10), 2041-2055
    DOI 10.1002/1878-0261.13476, PubMed 37341140
  11. Isaksen KT, Galleberg R, Mastroianni MA, Rinde M, Rusten LS, Barzenje D, Ramslien F, Fluge O, Slaaen M, Meyer P, Liestol K, Smeland EB, Lingjarde OC, Holte H, Brodtkorb M (2023)
    The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
    Haematologica, 108 (9), 2454-2466
    DOI 10.3324/haematol.2022.282289, PubMed 36861406
  12. Johanssen T, McVeigh L, Erridge S, Higgins G, Straehla J, Frame M, Aittokallio T, Carragher NO, Ebner D (2023)
    Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
    Front Oncol, 12, 1075559
    DOI 10.3389/fonc.2022.1075559, PubMed 36733367
  13. Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
    Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
    Front Oncol, 13, 1217424
    DOI 10.3389/fonc.2023.1217424, PubMed 37476372
  14. Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
    Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
    Eur J Cancer, 194, 113278
    DOI 10.1016/j.ejca.2023.113278, PubMed 37820553
  15. Levy-Jurgenson A, Tekpli X, Kristensen VN, Yakhini Z (2023)
    Analysis of Spatial Molecular Data
    Methods Mol Biol, 2614, 349-356
    DOI 10.1007/978-1-0716-2914-7_20, PubMed 36587134
  16. Lorenzovici L, Szilberhorn L, Farkas-Ráduly S, Gasparik AI, Precup AM, Nagy AG, Niemann CU, Aittokallio T, Kaló Z, Csanádi M (2023)
    Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia
    BioDrugs, 37 (2), 219-233
    DOI 10.1007/s40259-023-00583-9, PubMed 36795353
  17. Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
    MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
    Cancers (Basel), 15 (18)
    DOI 10.3390/cancers15184662, PubMed 37760629
  18. Nguyen HL, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, Brock J, Broeks A, Caldas C, Cardoso F, De Schepper M, Delorenzi M, Drukker CA, Glas AM, Green AR, Isnaldi E, Eyfjörð J, Khout H, Knappskog S, Krishnamurthy S, Lakhani SR, Langerod A, Martens JWM, McCart Reed AE, Murphy L et al. (2023)
    Obesity-associated changes in molecular biology of primary breast cancer
    Nat Commun, 14 (1), 4418
    DOI 10.1038/s41467-023-39996-z, PubMed 37479706
  19. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
    A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
    Cancer Res Commun, 3 (2), 235-244
    DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
  20. Otte M, Stachelscheid J, Glaß M, Wahnschaffe L, Jiang Q, Lone W, Ianevski A, Aittokallio T, Iqbal J, Hallek M, Hüttelmaier S, Schrader A, Braun T, Herling M (2023)
    The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL
    Cancers (Basel), 15 (9)
    DOI 10.3390/cancers15092527, PubMed 37173993
  21. Połeć A, Ekstrøm PO, Fougner C, Sørlie T, Norum JH (2023)
    Rapid assessment of 3-dimensional intra-tumor heterogeneity through cycling temperature capillary electrophoresis
    BMC Res Notes, 16 (1), 167
    DOI 10.1186/s13104-023-06437-5, PubMed 37568187
  22. Potdar S, Ianevski F, Ianevski A, Tanoli Z, Wennerberg K, Seashore-Ludlow B, Kallioniemi O, Östling P, Aittokallio T, Saarela J (2023)
    Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
    Nucleic Acids Res, 51 (W1), W57-W61
    DOI 10.1093/nar/gkad390, PubMed 37178002
  23. Rakaee M, Andersen S, Giannikou K, Paulsen EE, Kilvaer TK, Busund LR, Berg T, Richardsen E, Lombardi AP, Adib E, Pedersen MI, Tafavvoghi M, Wahl SGF, Petersen RH, Bondgaard AL, Yde CW, Baudet C, Licht P, Lund-Iversen M, Grønberg BH, Fjellbirkeland L, Helland Å, Pøhl M, Kwiatkowski DJ, Donnem T (2023)
    Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
    Ann Oncol, 34 (7), 578-588
    DOI 10.1016/j.annonc.2023.04.005, PubMed 37100205
  24. Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
    Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
    Acta Oncol, 62 (1), 8-14
    DOI 10.1080/0284186X.2023.2175331, PubMed 36762472
  25. Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
    New centres to carry out more clinical trials in Norway
    Tidsskr Nor Laegeforen, 143 (2)
    DOI 10.4045/tidsskr.22.0722, PubMed 36718905
  26. Stashko C, Hayward MK, Northey JJ, Pearson N, Ironside AJ, Lakins JN, Oria R, Goyette MA, Mayo L, Russnes HG, Hwang ES, Kutys ML, Polyak K, Weaver VM (2023)
    A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer
    Nat Commun, 14 (1), 3561
    DOI 10.1038/s41467-023-39085-1, PubMed 37322009
  27. van Amerongen R, Bentires-Alj M, van Boxtel AL, Clarke RB, Fre S, Suarez EG, Iggo R, Jechlinger M, Jonkers J, Mikkola ML, Koledova ZS, Sørlie T, Vivanco MD (2023)
    Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research
    J Mammary Gland Biol Neoplasia, 28 (1), 17
    DOI 10.1007/s10911-023-09544-y, PubMed 37450065
  28. Vitelli V, Fleischer T, Ankill J, Arjas E, Frigessi A, Kristensen VN, Zucknick M (2023)
    Transcriptomic pan-cancer analysis using rank-based Bayesian inference
    Mol Oncol, 17 (4), 548-563
    DOI 10.1002/1878-0261.13354, PubMed 36562628
  29. Wang MM, Coupland SE, Aittokallio T, Figueiredo CR (2023)
    Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities
    Br J Cancer, 129 (8), 1212-1224
    DOI 10.1038/s41416-023-02361-4, PubMed 37454231
  30. Wu Y, Wang Z, Zhao Z, Song X, Miao M, Zhang X (2023)
    Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus: Results from a prospective cohort study
    Diabetes Obes Metab, 25 (8), 2255-2267
    DOI 10.1111/dom.15104, PubMed 37161712

Publications 2022

  1. Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Augustinsson A, Baten A, Becher H, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H et al. (2022)
    Common variants in breast cancer risk loci predispose to distinct tumor subtypes
    Breast Cancer Res, 24 (1), 2
    DOI 10.1186/s13058-021-01484-x, PubMed 34983606
  2. Aittokallio T (2022)
    What are the current challenges for machine learning in drug discovery and repurposing?
    Expert Opin Drug Discov, 17 (5), 423-425
    DOI 10.1080/17460441.2022.2050694, PubMed 35255749
  3. Alexeyenko A, Brustugun OT, Eide IJZ, Gencheva R, Kosibaty Z, Lai Y, de Petris L, Tsakonas G, Grundberg O, Franzen B, Viktorsson K, Lewensohn R, Hydbring P, Ekman S (2022)
    Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
    Transl Lung Cancer Res, 11 (10), 2064-2078
    DOI 10.21037/tlcr-22-236, PubMed 36386450
  4. Alver TN, Heintz KM, Hovig E, Bøe SL (2022)
    Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway
    Cancer Rep (Hoboken), 6 (2), e1736
    DOI 10.1002/cnr2.1736, PubMed 36251678
  5. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
    ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
    JCO Precis Oncol, 6 (1), e2200015
    DOI 10.1200/PO.22.00015, PubMed 35476549
  6. Ankill J, Aure MR, Bjørklund S, Langberg S, Oslo Breast Cancer Consortium (OSBREAC) , Kristensen VN, Vitelli V, Tekpli X, Fleischer T (2022)
    Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer
    NAR Cancer, 4 (1), zcac008
    DOI 10.1093/narcan/zcac008, PubMed 35350772
  7. Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T (2022)
    Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
    Methods Mol Biol, 2449, 327-348
    DOI 10.1007/978-1-0716-2095-3_14, PubMed 35507270
  8. Ballester PJ, Stevens R, Haibe-Kains B, Huang RS, Aittokallio T (2022)
    Artificial intelligence for drug response prediction in disease models
    Brief Bioinform, 23 (1)
    DOI 10.1093/bib/bbab450, PubMed 34655289
  9. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
    Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
    Front Immunol, 13, 875152
    DOI 10.3389/fimmu.2022.875152, PubMed 35911763
  10. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
    Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
    Front Immunol, 13, 1051156
    DOI 10.3389/fimmu.2022.1051156, PubMed 36263024
  11. Bergholtz H, Lien T, Lingaas F, Sørlie T (2022)
    Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors
    J Mammary Gland Biol Neoplasia, 27 (2), 171-183
    DOI 10.1007/s10911-022-09523-9, PubMed 35932380
  12. Bjørklund SS, Aure MR, Häkkinen J, Vallon-Christersson J, Kumar S, Evensen KB, Fleischer T, Tost J, OSBREAC, Sahlberg KK, Mathelier A, Bhanot G, Ganesan S, Tekpli X, Kristensen VN (2022)
    Subtype and cell type specific expression of lncRNAs provide insight into breast cancer
    Commun Biol, 5 (1), 834
    DOI 10.1038/s42003-022-03559-7, PubMed 35982125
  13. Børø S, Thoresen S, Helland Å (2022)
    Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
    Front Oncol, 12, 1017902
    DOI 10.3389/fonc.2022.1017902, PubMed 36523970
  14. Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
    Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
    Br J Cancer, 127 (3), 500-513
    DOI 10.1038/s41416-022-01816-4, PubMed 35440666
  15. Callesen LB, Takacova T, Hamfjord J, Würschmidt F, Oldhafer KJ, Brüning R, Arnold D, Spindler KG (2022)
    Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
    Ther Adv Med Oncol, 14, 17588359221133171
    DOI 10.1177/17588359221133171, PubMed 36339929
  16. Castro-Mondragon JA, Aure MR, Lingjærde OC, Langerød A, Martens JWM, Børresen-Dale AL, Kristensen VN, Mathelier A (2022)
    Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers
    Nucleic Acids Res, 50 (21), 12131-12148
    DOI 10.1093/nar/gkac1143, PubMed 36477895
  17. Chen J, Song Y, Li Y, Wei Y, Shen S, Zhao Y, You D, Su L, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Shen H, Christiani DC, Zhang R, Chen F (2022)
    A trans-omics assessment of gene-gene interaction in early-stage NSCLC
    Mol Oncol, 17 (1), 173-187
    DOI 10.1002/1878-0261.13345, PubMed 36408734
  18. Denisova OV, Merisaari J, Kaur A, Yetukuri L, Jumppanen M, von Schantz-Fant C, Ohlmeyer M, Wennerberg K, Aittokallio T, Taipale M, Westermarck J (2022)
    Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells
    Sci Rep, 12 (1), 13796
    DOI 10.1038/s41598-022-18118-7, PubMed 35963891
  19. Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
    Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
    Cancers (Basel), 14 (19)
    DOI 10.3390/cancers14194859, PubMed 36230782
  20. Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
    Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
    Transl Lung Cancer Res, 11 (6), 953-963
    DOI 10.21037/tlcr-21-995, PubMed 35832438
  21. Eliseussen E, Fleischer T, Vitelli V (2022)
    Rank-based Bayesian variable selection for genome-wide transcriptomic analyses
    Stat Med, 41 (23), 4532-4553
    DOI 10.1002/sim.9524, PubMed 35844145
  22. Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG (2022)
    Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
    Trends Pharmacol Sci, 43 (11), 973-985
    DOI 10.1016/j.tips.2022.08.009, PubMed 36163057
  23. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
    Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
    J Thorac Oncol, 18 (2), 181-193
    DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040
  24. Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
    [Checkpoint inhibitor-induced myocarditis]
    Tidsskr Nor Laegeforen, 142 (18)
    DOI 10.4045/tidsskr.21.0817, PubMed 36511752
  25. Halkola AS, Aittokallio T, Parvinen K (2022)
    Tumor microenvironment as a metapopulation model: The effects of angiogenesis, emigration and treatment modalities
    J Theor Biol, 545, 111147
    DOI 10.1016/j.jtbi.2022.111147, PubMed 35489642
  26. Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E (2022)
    EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    Cancer Treat Res Commun, 33, 100636
    DOI 10.1016/j.ctarc.2022.100636, PubMed 36155129
  27. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    J Transl Med, 20 (1), 225
    DOI 10.1186/s12967-022-03432-5, PubMed 35568909
  28. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    J Transl Med, 20 (1), 317
    DOI 10.1186/s12967-022-03518-0, PubMed 35841045
  29. Hjerkind KV, Johansson ALV, Trewin CB, Russnes HG, Ursin G (2022)
    Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway
    Breast Cancer Res, 24 (1), 4
    DOI 10.1186/s13058-021-01498-5, PubMed 35012613
  30. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
    Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
    Mol Oncol, 17 (3), 487-498
    DOI 10.1002/1878-0261.13330, PubMed 36330681
  31. Ianevski A, Giri AK, Aittokallio T (2022)
    Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
    Nat Commun, 13 (1), 1246
    DOI 10.1038/s41467-022-28803-w, PubMed 35273156
  32. Ianevski A, Giri AK, Aittokallio T (2022)
    SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
    Nucleic Acids Res, 50 (W1), W739-W743
    DOI 10.1093/nar/gkac382, PubMed 35580060
  33. Ji X, Lin L, Fan J, Li Y, Wei Y, Shen S, Su L, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Zhang R, Chen F, Christiani DC (2022)
    Epigenome-wide three-way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early-stage NSCLC
    Mol Oncol, 16 (3), 717-731
    DOI 10.1002/1878-0261.13167, PubMed 34932879
  34. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
    Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    Front Oncol, 12, 873532
    DOI 10.3389/fonc.2022.873532, PubMed 35574381
  35. Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T (2022)
    An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
    Leukemia, 36 (10), 2384-2395
    DOI 10.1038/s41375-022-01662-6, PubMed 35945345
  36. Kong W, Midena G, Chen Y, Athanasiadis P, Wang T, Rousu J, He L, Aittokallio T (2022)
    Systematic review of computational methods for drug combination prediction
    Comput Struct Biotechnol J, 20, 2807-2814
    DOI 10.1016/j.csbj.2022.05.055, PubMed 35685365
  37. Kosibaty Z, Brustugun OT, Zwicky Eide IJ, Tsakonas G, Grundberg O, De Petris L, McGowan M, Hydbring P, Ekman S (2022)
    Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
    Cancers (Basel), 14 (14)
    DOI 10.3390/cancers14143430, PubMed 35884490
  38. Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD et al. (2022)
    Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer
    Cancer Discov, 12 (12), 2930-2953
    DOI 10.1158/2159-8290.CD-21-0865, PubMed 36108220
  39. Lemma RB, Fleischer T, Martinsen E, Ledsaak M, Kristensen V, Eskeland R, Gabrielsen OS, Mathelier A (2022)
    Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers
    Epigenetics Chromatin, 15 (1), 13
    DOI 10.1186/s13072-022-00444-9, PubMed 35440061
  40. Lobert VH, Skardal ML, Malerød L, Simensen JE, Algra HA, Andersen AN, Fleischer T, Enserink HA, Liestøl K, Heath JK, Rusten TE, Stenmark HA (2022)
    PHLPP1 regulates CFTR activity and lumen expansion through AMPK
    Development, 149 (20)
    DOI 10.1242/dev.200955, PubMed 35997536
  41. Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
    A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
    Front Oncol, 12, 1031232
    DOI 10.3389/fonc.2022.1031232, PubMed 36439452
  42. Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
    Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
    Cancers (Basel), 14 (5)
    DOI 10.3390/cancers14051326, PubMed 35267636
  43. Murumägi A, Ungureanu D, Khan S, Arjama M, Välimäki K, Ianevski A, Ianevski P, Bergström R, Dini A, Kanerva A, Koivisto-Korander R, Tapper J, Lassus H, Loukovaara M, Mägi A, Hirasawa A, Aoki D, Pietiäinen V, Pellinen T, Bützow R, Aittokallio T, Kallioniemi O (2022)
    Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
    Br J Cancer, 128 (4), 678-690
    DOI 10.1038/s41416-022-02067-z, PubMed 36476658
  44. Pedersen CA, Cao MD, Fleischer T, Rye MB, Knappskog S, Eikesdal HP, Lønning PE, Tost J, Kristensen VN, Tessem MB, Giskeødegård GF, Bathen TF (2022)
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
    Breast Cancer Res, 24 (1), 43
    DOI 10.1186/s13058-022-01537-9, PubMed 35751095
  45. Ravindran V, Wagoner J, Athanasiadis P, Den Hartigh AB, Sidorova JM, Ianevski A, Fink SL, Frigessi A, White J, Polyak SJ, Aittokallio T (2022)
    Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network
    Brief Bioinform, 23 (6)
    DOI 10.1093/bib/bbac456, PubMed 36305426
  46. Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
    Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
    Acta Oncol, 61 (8), 955-962
    DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
  47. Seborova K, Hlavac V, Holy P, Bjørklund SS, Fleischer T, Rob L, Hruda M, Bouda J, Mrhalova M, Allah MMKAO, Vodicka P, Fiala O, Soucek P, Kristensen VN, Vodickova L, Vaclavikova R (2022)
    Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy
    Front Oncol, 12, 1016958
    DOI 10.3389/fonc.2022.1016958, PubMed 36531044
  48. Silwal-Pandit L, Stålberg SM, Henrik J. Johansson, Georgios Mermelekas, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal D, Helland, Lingjærde OC, Labori KJ, Skålhegg BS, Janne Lehtiö, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    Cancer Res Commun, 2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PublikaID 411
  49. Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    Cancer Res Commun, 2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555
  50. Smirnov P, Smith I, Safikhani Z, Ba-Alawi W, Khodakarami F, Lin E, Yu Y, Martin S, Ortmann J, Aittokallio T, Hafner M, Haibe-Kains B (2022)
    Evaluation of statistical approaches for association testing in noisy drug screening data
    BMC Bioinformatics, 23 (1), 188
    DOI 10.1186/s12859-022-04693-z, PubMed 35585485
  51. Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J (2022)
    RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
    NPJ Breast Cancer, 8 (1), 94
    DOI 10.1038/s41523-022-00465-3, PubMed 35974007
  52. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
  53. Umu SU, Langseth H, Zuber V, Helland Å, Lyle R, Rounge TB (2022)
    Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
    Elife, 11
    DOI 10.7554/eLife.71035, PubMed 35147498
  54. Wang T, Pulkkinen OI, Aittokallio T (2022)
    Target-specific compound selectivity for multi-target drug discovery and repurposing
    Front Pharmacol, 13, 1003480
    DOI 10.3389/fphar.2022.1003480, PubMed 36225560
  55. Wolf J, Helland Å, Oh IJ, Migliorino MR, Dziadziuszko R, Wrona A, de Castro J, Mazieres J, Griesinger F, Chlistalla M, Cardona A, Ruf T, Trunzer K, Smoljanovic V, Novello S (2022)
    Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
    ESMO Open, 7 (1), 100333
    DOI 10.1016/j.esmoop.2021.100333, PubMed 35042152
  56. Wolowczyk C, Neckmann U, Aure MR, Hall M, Johannessen B, Zhao S, Skotheim RI, Andersen SB, Zwiggelaar R, Steigedal TS, Lingjærde OC, Sahlberg KK, Almaas E, Bjørkøy G (2022)
    NRF2 drives an oxidative stress response predictive of breast cancer
    Free Radic Biol Med, 184, 170-184
    DOI 10.1016/j.freeradbiomed.2022.03.029, PubMed 35381325
  57. Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS (2022)
    Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
    Clin Cancer Res, 28 (20), 4444-4455
    DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013
  58. Zhao Z, Wang S, Zucknick M, Aittokallio T (2022)
    Tissue-specific identification of multi-omics features for pan-cancer drug response prediction
    iScience, 25 (8), 104767
    DOI 10.1016/j.isci.2022.104767, PubMed 35992090
  59. Zhao Z, Zucknick M, Aittokallio T (2022)
    EnrichIntersect: an R package for custom set enrichment analysis and interactive visualization of intersecting sets
    Bioinform Adv, 2 (1), vbac073
    DOI 10.1093/bioadv/vbac073, PubMed 36699400

Publications 2021

  1. Akimov Y, Aittokallio T (2021)
    Re-defining synthetic lethality by phenotypic profiling for precision oncology
    Cell Chem Biol, 28 (3), 246-256
    DOI 10.1016/j.chembiol.2021.01.026, PubMed 33631125
  2. Aure MR, Fleischer T, Bjørklund S, Ankill J, Castro-Mondragon JA, OSBREAC, Børresen-Dale AL, Tost J, Sahlberg KK, Mathelier A, Tekpli X, Kristensen VN (2021)
    Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
    Genome Med, 13 (1), 72
    DOI 10.1186/s13073-021-00880-4, PubMed 33926515
  3. Bahrami N, Jabeen S, Tahiri A, Sauer T, Ødegård HP, Geisler SB, Gravdehaug B, Reitsma LC, Selsås K, Kristensen V, Geisler J (2021)
    Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
    Breast Cancer Res Treat, 190 (3), 435-449
    DOI 10.1007/s10549-021-06399-x, PubMed 34554372
  4. Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, Fachal L, Michailidou K, Bolla MK, Wang Q, Dennis J, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE et al. (2021)
    Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
    Am J Hum Genet, 108 (7), 1190-1203
    DOI 10.1016/j.ajhg.2021.05.013, PubMed 34146516
  5. Ben-Elazar S, Aure MR, Jonsdottir K, Leivonen SK, Kristensen VN, Janssen EAM, Kleivi Sahlberg K, Lingjærde OC, Yakhini Z (2021)
    miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
    PLoS Comput Biol, 17 (2), e1008608
    DOI 10.1371/journal.pcbi.1008608, PubMed 33566819
  6. Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
    Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
    Front Oncol, 11, 674731
    DOI 10.3389/fonc.2021.674731, PubMed 34109123
  7. Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I et al. (2021)
    Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
    Cancers (Basel), 13 (17)
    DOI 10.3390/cancers13174456, PubMed 34503266
  8. Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
    Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
    BMC Cancer, 21 (1), 1089
    DOI 10.1186/s12885-021-08811-7, PubMed 34625038
  9. Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
    Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
    Phys Imaging Radiat Oncol, 18, 51-54
    DOI 10.1016/j.phro.2021.04.003, PubMed 34258408
  10. Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C et al. (2021)
    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
    N Engl J Med, 384 (5), 428-439
    DOI 10.1056/NEJMoa1913948, PubMed 33471991
  11. Brück OE, Lallukka-Brück SE, Hohtari HR, Ianevski A, Ebeling FT, Kovanen PE, Kytölä SI, Aittokallio TA, Ramos PM, Porkka KV, Mustjoki SM (2021)
    Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS
    Blood Cancer Discov, 2 (3), 238-249
    DOI 10.1158/2643-3230.BCD-20-0162, PubMed 34661156
  12. Cichońska A, Ravikumar B, Allaway RJ, Wan F, Park S, Isayev O, Li S, Mason M, Lamb A, Tanoli Z, Jeon M, Kim S, Popova M, Capuzzi S, Zeng J, Dang K, Koytiger G, Kang J, Wells CI, Willson TM, IDG-DREAM Drug-Kinase Binding Prediction Challenge Consortium, Oprea TI, Schlessinger A, Drewry DH, Stolovitzky G et al. (2021)
    Crowdsourced mapping of unexplored target space of kinase inhibitors
    Nat Commun, 12 (1), 3307
    DOI 10.1038/s41467-021-23165-1, PubMed 34083538
  13. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
    Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
    Acta Oncol, 60 (12), 1565-1571
    DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
  14. Erdélyi K, Ditrói T, Johansson HJ, Czikora Á, Balog N, Silwal-Pandit L, Ida T, Olasz J, Hajdú D, Mátrai Z, Csuka O, Uchida K, Tóvári J, Engebraten O, Akaike T, Børresen Dale AL, Kásler M, Lehtiö J, Nagy P (2021)
    Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
    Proc Natl Acad Sci U S A, 118 (45)
    DOI 10.1073/pnas.2100050118, PubMed 34737229
  15. Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
    [Immunotherapy for malignant pleural mesothelioma]
    Tidsskr Nor Laegeforen, 141
    DOI 10.4045/tidsskr.21.0503, PubMed 34505475
  16. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
    Immunotherapy in malignant pleural mesothelioma
    Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
  17. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falcó A, Van't Veer LJ, Schmidt M, Quigley DA, Børresen-Dale AL, Kristensen VN, Balmain A, Climent J (2021)
    Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression
    NPJ Breast Cancer, 7 (1), 118
    DOI 10.1038/s41523-021-00329-2, PubMed 34508103
  18. Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
    The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
    Front Immunol, 12, 764596
    DOI 10.3389/fimmu.2021.764596, PubMed 34868011
  19. Galili B, Tekpli X, Kristensen VN, Yakhini Z (2021)
    Efficient gene expression signature for a breast cancer immuno-subtype
    PLoS One, 16 (1), e0245215
    DOI 10.1371/journal.pone.0245215, PubMed 33434192
  20. Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
    Int J Cancer, 149 (6), 1385-1397
    DOI 10.1002/ijc.33672, PubMed 33961700
  21. Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
    Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
    Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
    DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022
  22. Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
    Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
    JCO Precis Oncol, 5
    DOI 10.1200/PO.20.00086, PubMed 34036235
  23. He C, Micallef L, He L, Peddinti G, Aittokallio T, Jacucci G (2021)
    Characterizing the Quality of Insight by Interactions: A Case Study
    IEEE Trans Vis Comput Graph, 27 (8), 3410-3424
    DOI 10.1109/TVCG.2020.2977634, PubMed 32142444
  24. Herring S, Oda JM, Wagoner J, Kirchmeier D, O'Connor A, Nelson EA, Huang Q, Liang Y, DeWald LE, Johansen LM, Glass PJ, Olinger GG, Ianevski A, Aittokallio T, Paine MF, Fink SL, White JM, Polyak SJ (2021)
    Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
    Antimicrob Agents Chemother, 65 (4)
    DOI 10.1128/AAC.01146-20, PubMed 33468464
  25. Herring S, Oda JM, Wagoner J, Kirchmeier D, O'Connor A, Nelson EA, Huang Q, Liang Y, DeWald LE, Johansen LM, Glass PJ, Olinger GG, Ianevski A, Aittokallio T, Paine MF, Fink SL, White JM, Polyak SJ (2021)
    Erratum for Herring et al., "Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs"
    Antimicrob Agents Chemother, 65 (6)
    DOI 10.1128/AAC.00653-21, PubMed 34006613
  26. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
    NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    J Transl Med, 19 (1), 232
    DOI 10.1186/s12967-021-02905-3, PubMed 34059094
  27. Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T (2021)
    Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
    Sci Adv, 7 (8)
    DOI 10.1126/sciadv.abe4038, PubMed 33608276
  28. Jaiswal A, Gautam P, Pietilä EA, Timonen S, Nordström N, Akimov Y, Sipari N, Tanoli Z, Fleischer T, Lehti K, Wennerberg K, Aittokallio T (2021)
    Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
    Mol Syst Biol, 17 (3), e9526
    DOI 10.15252/msb.20209526, PubMed 33750001
  29. Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K (2021)
    The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
    JCI Insight, 6 (11)
    DOI 10.1172/jci.insight.147617, PubMed 33886505
  30. Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
    COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
    Front Oncol, 11, 652535
    DOI 10.3389/fonc.2021.652535, PubMed 33842366
  31. Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G (2021)
    In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
    Breast Cancer Res, 23 (1), 17
    DOI 10.1186/s13058-021-01393-z, PubMed 33526044
  32. Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
    Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
    Sci Rep, 11 (1), 3388
    DOI 10.1038/s41598-021-81914-0, PubMed 33564016
  33. Lai X, Taskén HA, Mo T, Funke SW, Frigessi A, Rognes ME, Köhn-Luque A (2021)
    A scalable solver for a stochastic, hybrid cellular automaton model of personalized breast cancer therapy
    Int J Numer Method Biomed Eng, 38 (1), e3542
    DOI 10.1002/cnm.3542, PubMed 34716985
  34. Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ et al. (2021)
    Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
    Nat Cancer, 2 (11), 1224-1242
    DOI 10.1038/s43018-021-00259-9, PubMed 34870237
  35. Levy-Jurgenson A, Tekpli X, Yakhini Z (2021)
    Assessing heterogeneity in spatial data using the HTA index with applications to spatial transcriptomics and imaging
    Bioinformatics, 37 (21), 3796-3804
    DOI 10.1093/bioinformatics/btab569, PubMed 34358288
  36. Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, Osbreac OBO, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2021)
    Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
    Cancers (Basel), 13 (23)
    DOI 10.3390/cancers13236118, PubMed 34885228
  37. Lilleborge M, Falk RS, Sørlie T, Ursin G, Hofvind S (2021)
    Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion
    Int J Cancer, 149 (6), 1247-1256
    DOI 10.1002/ijc.33680, PubMed 33990967
  38. Lingjærde C, Lien TG, Borgan Ø, Bergholtz H, Glad IK (2021)
    Tailored graphical lasso for data integration in gene network reconstruction
    BMC Bioinformatics, 22 (1), 498
    DOI 10.1186/s12859-021-04413-z, PubMed 34654363
  39. Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA et al. (2021)
    Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
    Cancer Discov, 12 (2), 388-401
    DOI 10.1158/2159-8290.CD-21-0410, PubMed 34789538
  40. Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brüning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J et al. (2021)
    Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
    Breast Cancer Res, 23 (1), 86
    DOI 10.1186/s13058-021-01450-7, PubMed 34407845
  41. Maagdenberg H, Oosterom N, Zanen J, Gemmati D, Windsor RE, Heil SG, Esperón P, Jabeen S, Ruiz-Argüelles GJ, Zolk O, Hoerning S, Sleurs C, Lopéz-Lopéz E, Moreno-Galván M, van den Heuvel-Eibrink MM, Maitland-van der Zee AH, Carleton BC (2021)
    Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis
    Crit Rev Oncol Hematol, 161, 103312
    DOI 10.1016/j.critrevonc.2021.103312, PubMed 33794308
  42. Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
    Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
    Sci Rep, 11 (1), 6317
    DOI 10.1038/s41598-021-85613-8, PubMed 33737576
  43. Park J, Choi JY, Choi J, Chung S, Song N, Park SK, Han W, Noh DY, Ahn SH, Lee JW, Kim MK, Jee SH, Wen W, Bolla MK, Wang Q, Dennis J, Michailidou K, Shah M, Conroy DM, Harrington PA, Mayes R, Czene K, Hall P, Teras LR, Patel AV et al. (2021)
    Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
    Cancers (Basel), 13 (10)
    DOI 10.3390/cancers13102370, PubMed 34069208
  44. Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
    Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
    Mol Oncol, 16 (1), 88-103
    DOI 10.1002/1878-0261.13047, PubMed 34165864
  45. Siddiqui FA, Parkkola H, Vukic V, Oetken-Lindholm C, Jaiswal A, Kiriazis A, Pavic K, Aittokallio T, Salminen TA, Abankwa D (2021)
    Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
    Cancers (Basel), 13 (4)
    DOI 10.3390/cancers13040927, PubMed 33672199
  46. Tanoli Z, Vähä-Koskela M, Aittokallio T (2021)
    Artificial intelligence, machine learning, and drug repurposing in cancer
    Expert Opin Drug Discov, 16 (9), 977-989
    DOI 10.1080/17460441.2021.1883585, PubMed 33543671
  47. Terkelsen T, Pernemalm M, Gromov P, Børresen-Dale AL, Krogh A, Haakensen VD, Lethiö J, Papaleo E, Gromova I (2021)
    High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
    Mol Oncol, 15 (2), 429-461
    DOI 10.1002/1878-0261.12850, PubMed 33176066
  48. Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S et al. (2021)
    Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
    J Med Chem, 64 (12), 8486-8509
    DOI 10.1021/acs.jmedchem.1c00420, PubMed 34101461
  49. Wahl SGF, Dai HY, Emdal EF, Berg T, Halvorsen TO, Ottestad AL, Lund-Iversen M, Brustugun OT, Førde D, Paulsen EE, Donnem T, Andersen S, Grønberg BH, Richardsen E (2021)
    The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
    Cancers (Basel), 13 (17)
    DOI 10.3390/cancers13174294, PubMed 34503114
  50. Wang T, Szedmak S, Wang H, Aittokallio T, Pahikkala T, Cichonska A, Rousu J (2021)
    Modeling drug combination effects via latent tensor reconstruction
    Bioinformatics, 37 (Suppl_1), i93-i101
    DOI 10.1093/bioinformatics/btab308, PubMed 34252952
  51. White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, Wennerberg K, Guinney J (2021)
    Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
    NPJ Precis Oncol, 5 (1), 71
    DOI 10.1038/s41698-021-00209-9, PubMed 34302041
  52. White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ (2021)
    Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
    mBio, 12 (6), e0334721
    DOI 10.1128/mbio.03347-21, PubMed 34933447
  53. White JM, Schiffer JT, Ignacio RAB, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ (2021)
    Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
    mBio, 12 (6), e03347-21
  54. Xu H, Lien T, Bergholtz H, Fleischer T, Djerroudi L, Vincent-Salomon A, Sørlie T, Aittokallio T (2021)
    Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression
    Front Genet, 12, 670749
    DOI 10.3389/fgene.2021.670749, PubMed 34149812
  55. Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å (2021)
    Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
    Mol Oncol, 15 (11), 2958-2968
    DOI 10.1002/1878-0261.13082, PubMed 34402187
  56. Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
    Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
    Int J Cancer, 150 (1), 100-111
    DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

  1. Abravan A, Eide HA, Helland Å, Malinen E (2020)
    Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
    Clin Transl Radiat Oncol, 22, 15-21
    DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373
  2. Akimov Y, Bulanova D, Timonen S, Wennerberg K, Aittokallio T (2020)
    Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics
    Mol Syst Biol, 16 (3), e9195
    DOI 10.15252/msb.20199195, PubMed 32187448
  3. Ask EH, Tschan-Plessl A, Gjerdingen TJ, Sætersmoen ML, Hoel HJ, Wiiger MT, Olweus J, Wahlin BE, Lingjærde OC, Horowitz A, Cashen AF, Watkins M, Fehniger TA, Holte H, Kolstad A, Malmberg KJ (2020)
    A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
    Med, 2 (2), 180-195.e5
    DOI 10.1016/j.medj.2020.10.006, PubMed 35590201
  4. Bergholtz H, Kumar S, Wärnberg F, Lüders T, Kristensen V, Sørlie T (2020)
    Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer
    Cancer Rep (Hoboken), 3 (3), e1248
    DOI 10.1002/cnr2.1248, PubMed 32671987
  5. Bergholtz H, Lien TG, Swanson DM, Frigessi A, Oslo Breast Cancer Research Consortium (OSBREAC), Daidone MG, Tost J, Wärnberg F, Sørlie T (2020)
    Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
    NPJ Breast Cancer, 6, 26
    DOI 10.1038/s41523-020-0167-x, PubMed 32577501
  6. Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
    Lung cancer: Improved prognosis presents capacity challenges
    Tidsskr. Nor. Laegeforen., 140 (5), 432-434
  7. Chen C, Wei Y, Wei L, Chen J, Chen X, Dong X, He J, Lin L, Zhu Y, Huang H, You D, Lai L, Shen S, Duan W, Su L, Shafer A, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Zhang R et al. (2020)
    Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
    Aging (Albany NY), 12 (11), 10642-10662
    DOI 10.18632/aging.103284, PubMed 32511103
  8. Egeland NG, Jonsdottir K, Aure MR, Sahlberg K, Kristensen VN, Cronin-Fenton D, Skaland I, Gudlaugsson E, Baak JPA, Janssen EAM (2020)
    MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers
    BMC Cancer, 20 (1), 377
    DOI 10.1186/s12885-020-06857-7, PubMed 32370743
  9. Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
    Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Lung Cancer, 143, 27-35
    DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
  10. Engelsen AST, Wnuk-Lipinska K, Bougnaud S, Pelissier Vatter FA, Tiron C, Villadsen R, Miyano M, Lotsberg ML, Madeleine N, Panahandeh P, Dhakal S, Tan TZ, Peters SD, Grøndal S, Aziz SM, Nord S, Herfindal L, Stampfer MR, Sørlie T, Brekken RA, Straume O, Halberg N, Gausdal G, Thiery JP, Akslen LA et al. (2020)
    AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
    iScience, 23 (11), 101649
    DOI 10.1016/j.isci.2020.101649, PubMed 33103086
  11. Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale AL, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C, Canzian F et al. (2020)
    A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
    Nat Commun, 11 (1), 312
    DOI 10.1038/s41467-019-14100-6, PubMed 31949161
  12. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V et al. (2020)
    Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
    Nat Genet, 52 (1), 56-73
    DOI 10.1038/s41588-019-0537-1, PubMed 31911677
  13. Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M et al. (2020)
    Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
    Genet Epidemiol, 44 (5), 442-468
    DOI 10.1002/gepi.22288, PubMed 32115800
  14. Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M, Baranašić D, Santana-Garcia W, Tan G, Chèneby J, Ballester B, Parcy F, Sandelin A, Lenhard B, Wasserman WW, Mathelier A (2020)
    JASPAR 2020: update of the open-access database of transcription factor binding profiles
    Nucleic Acids Res, 48 (D1), D87-D92
    DOI 10.1093/nar/gkz1001, PubMed 31701148
  15. Fougner C, Bergholtz H, Norum JH, Sørlie T (2020)
    Re-definition of claudin-low as a breast cancer phenotype
    Nat Commun, 11 (1), 1787
    DOI 10.1038/s41467-020-15574-5, PubMed 32286297
  16. Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
    Antibody combinations for optimized staining of macrophages in human lung tumours
    Scand J Immunol, 92 (1), e12889
    DOI 10.1111/sji.12889, PubMed 32299134
  17. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
    MirGeneDB 2.0: the metazoan microRNA complement
    Nucleic Acids Res, 48 (D1), D132-D141
    DOI 10.1093/nar/gkz885, PubMed 31598695
  18. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
    MirGeneDB 2.0: the metazoan microRNA complement
    Nucleic Acids Res, 48 (D1), D1172
    DOI 10.1093/nar/gkz1016, PubMed 31642479
  19. Goleva-Fjellet S, Bjurholt AM, Kure EH, Larsen IK, Støren Ø, Sæbø M (2020)
    Distribution of allele frequencies for genes associated with physical activity and/or physical capacity in a homogenous Norwegian cohort- a cross-sectional study
    BMC Genet, 21 (1), 8
    DOI 10.1186/s12863-020-0813-1, PubMed 31973699
  20. Graim K, Gorenshteyn D, Robinson DG, Carriero NJ, Cahill JA, Chakrabarti R, Goldschmidt MH, Durham AC, Funk J, Storey JD, Kristensen VN, Theesfeld CL, Sorenmo KU, Troyanskaya OG (2020)
    Modeling molecular development of breast cancer in canine mammary tumors
    Genome Res, 31 (2), 337-347
    DOI 10.1101/gr.256388.119, PubMed 33361113
  21. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
    Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
    Front Oncol, 10, 590755
    DOI 10.3389/fonc.2020.590755, PubMed 33324562
  22. Hovda T, Tsuruda K, Hoff SR, Sahlberg KK, Hofvind S (2020)
    Radiological review of prior screening mammograms of screen-detected breast cancer
    Eur Radiol, 31 (4), 2568-2579
    DOI 10.1007/s00330-020-07130-y, PubMed 33001307
  23. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
    Int J Cancer, 147 (10), 2957-2966
    DOI 10.1002/ijc.33121, PubMed 32468587
  24. Ianevski A, Giri AK, Aittokallio T (2020)
    SynergyFinder 2.0: visual analytics of multi-drug combination synergies
    Nucleic Acids Res, 48 (W1), W488-W493
    DOI 10.1093/nar/gkaa216, PubMed 32246720
  25. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020)
    Pan-cancer analysis of whole genomes
    Nature, 578 (7793), 82-93
    DOI 10.1038/s41586-020-1969-6, PubMed 32025007
  26. Ji X, Lin L, Shen S, Dong X, Chen C, Li Y, Zhu Y, Huang H, Chen J, Chen X, Wei L, He J, Duan W, Su L, Jiang Y, Fan J, Guan J, You D, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M et al. (2020)
    Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
    Mol Oncol, 14 (11), 2759-2774
    DOI 10.1002/1878-0261.12785, PubMed 33448640
  27. Julkunen H, Cichonska A, Gautam P, Szedmak S, Douat J, Pahikkala T, Aittokallio T, Rousu J (2020)
    Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
    Nat Commun, 11 (1), 6136
    DOI 10.1038/s41467-020-19950-z, PubMed 33262326
  28. Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS, Oslo Breast Cancer Research Consortium (OSBREAC), Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M (2020)
    The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
    Sci Rep, 10 (1), 1277
    DOI 10.1038/s41598-020-57759-4, PubMed 31992741
  29. Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H et al. (2020)
    Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
    Am J Hum Genet, 107 (5), 837-848
    DOI 10.1016/j.ajhg.2020.09.001, PubMed 33022221
  30. Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
    ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
    J Transl Med, 18 (1), 269
    DOI 10.1186/s12967-020-02421-w, PubMed 32620163
  31. Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell DG, Wikman H, Galizzi JP, Riise Bergheim I, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher MR, Pantel K et al. (2020)
    Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows
    Clin Chem, 66 (1), 149-160
    DOI 10.1373/clinchem.2019.306837, PubMed 31628139
  32. Levy-Jurgenson A, Tekpli X, Kristensen VN, Yakhini Z (2020)
    Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer
    Sci Rep, 10 (1), 18802
    DOI 10.1038/s41598-020-75708-z, PubMed 33139755
  33. Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O (2020)
    KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia
    Leukemia, 34 (10), 2780-2784
    DOI 10.1038/s41375-020-0978-7, PubMed 32678289
  34. Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
    DNA copy number motifs are strong and independent predictors of survival in breast cancer
    Commun Biol, 3 (1), 153
    DOI 10.1038/s42003-020-0884-6, PubMed 32242091
  35. Pulkkinen OI, Gautam P, Mustonen V, Aittokallio T (2020)
    Multiobjective optimization identifies cancer-selective combination therapies
    PLoS Comput Biol, 16 (12), e1008538
    DOI 10.1371/journal.pcbi.1008538, PubMed 33370253
  36. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
    Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
    Acta Oncol, 59 (7), 733-740
    DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
  37. Riis M (2020)
    Modern surgical treatment of breast cancer
    Ann Med Surg (Lond), 56, 95-107
    DOI 10.1016/j.amsu.2020.06.016, PubMed 32637082
  38. Riis M (2020)
    Future perspectives of surgical treatment of breast cancer
    Ann Med Surg (Lond), 59, 93-95
    DOI 10.1016/j.amsu.2020.09.021, PubMed 33005399
  39. Russnes HG (2020)
    Clinical trials in the era of precision cancer medicine - for the few or for the many?
    Acta Oncol, 59 (7), 731-732
    DOI 10.1080/0284186X.2020.1777582, PubMed 32579040
  40. Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
    The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
    Scand J Immunol, 92 (2), e12893
    DOI 10.1111/sji.12893, PubMed 32433774
  41. Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E (2020)
    Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
    Breast Cancer Res, 22 (1), 73
    DOI 10.1186/s13058-020-01295-6, PubMed 32605588
  42. Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
    Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
    Oncoimmunology, 9 (1), 1824644
    DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
  43. Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
    A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
    Mol Oncol, 14 (2), 235-247
    DOI 10.1002/1878-0261.12620, PubMed 31851411
  44. von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
    Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
    Int J Cancer, 147 (9), 2515-2525
    DOI 10.1002/ijc.33108, PubMed 32488909
  45. Wang T, Gautam P, Rousu J, Aittokallio T (2020)
    Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
    Comput Struct Biotechnol J, 18, 3819-3832
    DOI 10.1016/j.csbj.2020.11.001, PubMed 33335681
  46. Weber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, Leest PV, Azpurua MA, Tamminga M, Brudzewsky D, Rothwell DG, Mohan S, Sartori A, Lampignano R, Konigshofer Y, Sprenger-Haussels M, Wikman H, Bergheim IR, Kloten V, Schuuring E, Speicher MR, Heitzer E (2020)
    Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling
    Cancers (Basel), 12 (6)
    DOI 10.3390/cancers12061588, PubMed 32560092
  47. Yu H, Brustugun OT, Ekman S, Botling J, La Fleur L, Micke P, Solberg S, Berglund A, Rivard C, Hirsch FR (2020)
    Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Clin Lung Cancer, 22 (4), e555-e562
    DOI 10.1016/j.cllc.2020.09.018, PubMed 33214079
  48. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW et al. (2020)
    Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
    Nat Genet, 52 (6), 572-581
    DOI 10.1038/s41588-020-0609-2, PubMed 32424353
  49. Zhang R, Chen C, Dong X, Shen S, Lai L, He J, You D, Lin L, Zhu Y, Huang H, Chen J, Wei L, Chen X, Li Y, Guo Y, Duan W, Liu L, Su L, Shafer A, Fleischer T, Moksnes Bjaanæs M, Karlsson A, Planck M, Wang R, Staaf J et al. (2020)
    Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
    Chest, 158 (2), 808-819
    DOI 10.1016/j.chest.2020.01.048, PubMed 32113923
  50. Zhu Q, Tekpli X, Troyanskaya OG, Kristensen VN (2020)
    Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations
    Bioinformatics, 36 (4), 994-999
    DOI 10.1093/bioinformatics/btz709, PubMed 31529022
  51. Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
    Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
    Acta Oncol, 60 (2), 149-156
    DOI 10.1080/0284186X.2020.1854851, PubMed 33356733

Publications 2019

  1. Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E (2019)
    Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
    Mol Imaging Biol, 21 (2), 391-398
    DOI 10.1007/s11307-018-1226-7, PubMed 29916117
  2. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
    A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
    J Mammary Gland Biol Neoplasia, 24 (2), 163-175
    DOI 10.1007/s10911-018-09423-x, PubMed 30613869
  3. Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ (2019)
    Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
    Pancreatology, 19 (2), 316-324
    DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
  4. Brinkman AB, Nik-Zainal S, Simmer F, Rodríguez-González FG, Smid M, Alexandrov LB, Butler A, Martin S, Davies H, Glodzik D, Zou X, Ramakrishna M, Staaf J, Ringnér M, Sieuwerts A, Ferrari A, Morganella S, Fleischer T, Kristensen V, Gut M, van de Vijver MJ, Børresen-Dale AL, Richardson AL, Thomas G, Gut IG et al. (2019)
    Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation
    Nat Commun, 10 (1), 1749
    DOI 10.1038/s41467-019-09828-0, PubMed 30988298
  5. Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2019)
    Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
    Nat Commun, 10 (1), 525
    DOI 10.1038/s41467-019-08512-7, PubMed 30692535
  6. Dong X, Zhang R, He J, Lai L, Alolga RN, Shen S, Zhu Y, You D, Lin L, Chen C, Zhao Y, Duan W, Su L, Shafer A, Salama M, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Wei Y, Chen F et al. (2019)
    Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma
    Aging (Albany NY), 11 (16), 6312-6335
    DOI 10.18632/aging.102189, PubMed 31434796
  7. Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL et al. (2019)
    Two truncating variants in FANCC and breast cancer risk
    Sci Rep, 9 (1), 12524
    DOI 10.1038/s41598-019-48804-y, PubMed 31467304
  8. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL et al. (2019)
    Genome-wide association study of germline variants and breast cancer-specific mortality
    Br J Cancer, 120 (6), 647-657
    DOI 10.1038/s41416-019-0393-x, PubMed 30787463
  9. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A et al. (2019)
    Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
    Nat Commun, 10 (1), 1741
    DOI 10.1038/s41467-018-08053-5, PubMed 30988301
  10. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
    A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
    Transl Oncol, 12 (7), 951-958
    DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
  11. Fougner C, Bergholtz H, Kuiper R, Norum JH, Sørlie T (2019)
    Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers
    Breast Cancer Res, 21 (1), 85
    DOI 10.1186/s13058-019-1170-8, PubMed 31366361
  12. Gheorghe M, Sandve GK, Khan A, Chèneby J, Ballester B, Mathelier A (2019)
    A map of direct TF-DNA interactions in the human genome
    Nucleic Acids Res, 47 (4), e21
    DOI 10.1093/nar/gky1210, PubMed 30517703
  13. Gheorghe M, Sandve GK, Khan A, Chèneby J, Ballester B, Mathelier A (2019)
    A map of direct TF-DNA interactions in the human genome
    Nucleic Acids Res, 47 (14), 7715
    DOI 10.1093/nar/gkz582, PubMed 31251803
  14. Ha TJ, Zhang PGY, Robert R, Yeung J, Swanson DJ, Mathelier A, Wasserman WW, Im S, Itoh M, Kawaji H, Lassmann T, Daub CO, Arner E, FANTOM Consortium, Carninci P, Hayashizaki Y, Forrest ARR, Goldowitz D (2019)
    Identification of novel cerebellar developmental transcriptional regulators with motif activity analysis
    BMC Genomics, 20 (1), 718
    DOI 10.1186/s12864-019-6063-9, PubMed 31533632
  15. Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å (2019)
    Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
    Mol Oncol, 13 (12), 2604-2615
    DOI 10.1002/1878-0261.12571, PubMed 31505091
  16. Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
    Ann Oncol, 30 (7), 1088-1095
    DOI 10.1093/annonc/mdz139, PubMed 31046124
  17. Itkonen HM, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, Walker S, Mills IG (2019)
    High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
    Theranostics, 9 (8), 2183-2197
    DOI 10.7150/thno.30834, PubMed 31149037
  18. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV et al. (2019)
    Publisher Correction: Shared heritability and functional enrichment across six solid cancers
    Nat Commun, 10 (1), 4386
    DOI 10.1038/s41467-019-12095-8, PubMed 31548585
  19. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV et al. (2019)
    Shared heritability and functional enrichment across six solid cancers
    Nat Commun, 10 (1), 431
    DOI 10.1038/s41467-018-08054-4, PubMed 30683880
  20. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
    Breast cancer quantitative proteome and proteogenomic landscape
    Nat Commun, 10 (1), 1600
    DOI 10.1038/s41467-019-09018-y, PubMed 30962452
  21. Kraby MR, Opdahl S, Russnes HG, Bofin AM (2019)
    Microvessel density in breast cancer: the impact of field area on prognostic informativeness
    J Clin Pathol, 72 (4), 304-310
    DOI 10.1136/jclinpath-2018-205536, PubMed 30630872
  22. Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
    Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
    Cancer Res, 79 (16), 4293-4304
    DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
  23. Lee YS, Krishnan A, Oughtred R, Rust J, Chang CS, Ryu J, Kristensen VN, Dolinski K, Theesfeld CL, Troyanskaya OG (2019)
    A Computational Framework for Genome-wide Characterization of the Human Disease Landscape
    Cell Syst, 8 (2), 152-162.e6
    DOI 10.1016/j.cels.2018.12.010, PubMed 30685436
  24. Lindholm EM, Leivonen SK, Undlien E, Nebdal D, Git A, Caldas C, Børresen-Dale AL, Kleivi K (2019)
    miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
    Microrna, 8 (2), 155-165
    DOI 10.2174/2211536608666181206124922, PubMed 30520388
  25. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol Oncol, 13 (10), 2278-2296
    DOI 10.1002/1878-0261.12561, PubMed 31402562
  26. Madssen TS, Cao MD, Pladsen AV, Ottestad L, Sahlberg KK, Bathen TF, Giskeødegård GF (2019)
    Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities
    Metabolites, 9 (11)
    DOI 10.3390/metabo9110278, PubMed 31766128
  27. Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM (2019)
    TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
    J Natl Cancer Inst, 111 (11), 1202-1215
    DOI 10.1093/jnci/djz051, PubMed 30990221
  28. Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
    Int J Cancer, 146 (1), 223-235
    DOI 10.1002/ijc.32638, PubMed 31444972
  29. Norum JH, Frings O, Kasper M, Bergholtz H, Zell Thime H, Bergström Å, Andersson A, Kuiper R, Fredlund E, Sørlie T, Toftgård R (2019)
    GLI1-induced mammary gland tumours are transplantable and maintain major molecular features
    Int J Cancer, 146 (4), 1125-1138
    DOI 10.1002/ijc.32522, PubMed 31219615
  30. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
    PathTracer: High-sensitivity detection of differential pathway activity in tumours
    Sci Rep, 9 (1), 16332
    DOI 10.1038/s41598-019-52529-3, PubMed 31704995
  31. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P (2019)
    miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer
    Cell Rep, 29 (13), 4389-4406.e10
    DOI 10.1016/j.celrep.2019.11.085, PubMed 31875548
  32. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
    Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
    Cancer Immunol Res, 7 (5), 701-706
    DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
  33. Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-Bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-Kains B (2019)
    Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma
    JCO Clin Cancer Inform, 3, 1-16
    DOI 10.1200/CCI.18.00102, PubMed 31070984
  34. Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
    EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
    PLoS One, 14 (1), e0204186
    DOI 10.1371/journal.pone.0204186, PubMed 30703089
  35. Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W, Breast Cancer Association Consortium (2019)
    Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
    Int J Epidemiol, 48 (3), 795-806
    DOI 10.1093/ije/dyy201, PubMed 30277539
  36. Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, van de Vijver MJ, Richardson AL, MacGrogan G, Salgado R, van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR et al. (2019)
    The circular RNome of primary breast cancer
    Genome Res, 29 (3), 356-366
    DOI 10.1101/gr.238121.118, PubMed 30692147
  37. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
    Immune Cell Composition in Human Non-small Cell Lung Cancer
    Front Immunol, 9, 3101
    DOI 10.3389/fimmu.2018.03101, PubMed 30774636
  38. Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
    A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
    Haematologica, 104 (10), e460-e464
    DOI 10.3324/haematol.2018.209080, PubMed 30846496
  39. Swanson DM, Lien T, Bergholtz H, Sørlie T, Frigessi A (2019)
    A Bayesian two-way latent structure model for genomic data integration reveals few pan-genomic cluster subtypes in a breast cancer cohort
    Bioinformatics, 35 (23), 4886-4897
    DOI 10.1093/bioinformatics/btz381, PubMed 31077301
  40. Taylor-King JP, Baratchart E, Dhawan A, Coker EA, Rye IH, Russnes H, Chapman SJ, Basanta D, Marusyk A (2019)
    Simulated ablation for detection of cells impacting paracrine signalling in histology analysis
    Math Med Biol, 36 (1), 93-112
    DOI 10.1093/imammb/dqx022, PubMed 29452382
  41. Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
    An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
    Nat Commun, 10 (1), 5499
    DOI 10.1038/s41467-019-13329-5, PubMed 31796750
  42. Vaclavikova R, Klajic J, Brynychova V, Elsnerova K, Alnaes GIG, Tost J, Kristensen VN, Rob L, Kodet R, Skapa P, Mrhalova M, Soucek P (2019)
    Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma
    Oncol Rep, 42 (2), 763-774
    DOI 10.3892/or.2019.7186, PubMed 31173253
  43. Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y et al. (2019)
    SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
    Mol Oncol, 13 (5), 1235-1248
    DOI 10.1002/1878-0261.12482, PubMed 30924596
  44. Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC (2019)
    EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
    Epigenetics, 14 (2), 118-129
    DOI 10.1080/15592294.2019.1573066, PubMed 30665327
  45. Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å (2019)
    The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
    Mol Oncol, 13 (5), 1166-1179
    DOI 10.1002/1878-0261.12475, PubMed 30854794

Publications 2018

  1. Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
    Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
    BMC Cancer, 18 (1), 739
    DOI 10.1186/s12885-018-4659-0, PubMed 30005623
  2. Chèneby J, Gheorghe M, Artufel M, Mathelier A, Ballester B (2018)
    ReMap 2018: an updated atlas of regulatory regions from an integrative analysis of DNA-binding ChIP-seq experiments
    Nucleic Acids Res, 46 (D1), D267-D275
    DOI 10.1093/nar/gkx1092, PubMed 29126285
  3. Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2018)
    Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
    Nat Commun, 9 (1), 5397
    DOI 10.1038/s41467-018-07842-2, PubMed 30559362
  4. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
    Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
    Adv Radiat Oncol, 3 (2), 130-138
    DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
  5. Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G (2018)
    Number of Risky Lifestyle Behaviors and Breast Cancer Risk
    JNCI Cancer Spectr, 2 (3), pky030
    DOI 10.1093/jncics/pky030, PubMed 31360858
  6. Fornes O, Gheorghe M, Richmond PA, Arenillas DJ, Wasserman WW, Mathelier A (2018)
    MANTA2, update of the Mongo database for the analysis of transcription factor binding site alterations
    Sci Data, 5, 180141
    DOI 10.1038/sdata.2018.141, PubMed 30040077
  7. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
    Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
    J Thorac Oncol, 13 (12), 1906-1918
    DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492
  8. Głodzik D, Purdie C, Rye IH, Simpson PT, Staaf J, Span PN, Russnes HG, Nik-Zainal S (2018)
    Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
    Ann Oncol, 29 (11), 2223-2231
    DOI 10.1093/annonc/mdy404, PubMed 30252041
  9. Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC (2018)
    DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
    Cancer Epidemiol Biomarkers Prev, 27 (12), 1527-1535
    DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536
  10. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
    Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
    Acta Oncol, 57 (9), 1225-1231
    DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
  11. Helland A (2018)
    Groundbreaking basic research
    Tidsskr. Nor. Laegeforen., 138 (20), 1905
  12. Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
    Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
    Genome Med, 10 (1), 92
    DOI 10.1186/s13073-018-0601-y, PubMed 30497530
  13. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
    Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
    Oncoimmunology, 8 (2), e1537691
    DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
  14. Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
    Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
    Oncoimmunology, 7 (11), e1457598
    DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
  15. Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, Kristensen VN, Solvang HK (2018)
    Correction to: A systematic comparison of copy number alterations in four types of female cancer
    BMC Cancer, 18 (1), 80
    DOI 10.1186/s12885-017-3766-7, PubMed 29338700
  16. Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, Bessy A, Chèneby J, Kulkarni SR, Tan G, Baranasic D, Arenillas DJ, Sandelin A, Vandepoele K, Lenhard B, Ballester B, Wasserman WW, Parcy F, Mathelier A (2018)
    JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework
    Nucleic Acids Res, 46 (D1), D1284
    DOI 10.1093/nar/gkx1188, PubMed 29161433
  17. Khan A, Mathelier A, Zhang X (2018)
    Super-enhancers are transcriptionally more active and cell type-specific than stretch enhancers
    Epigenetics, 13 (9), 910-922
    DOI 10.1080/15592294.2018.1514231, PubMed 30169995
  18. Khan A, Montenegro-Montero A, Mathelier A (2018)
    Put science first and formatting later
    EMBO Rep, 19 (5)
    DOI 10.15252/embr.201845731, PubMed 29650529
  19. Lecellier CH, Wasserman WW, Mathelier A (2018)
    Human Enhancers Harboring Specific Sequence Composition, Activity, and Genome Organization Are Linked to the Immune Response
    Genetics, 209 (4), 1055-1071
    DOI 10.1534/genetics.118.301116, PubMed 29871881
  20. Mauger F, Kernaleguen M, Lallemand C, Kristensen VN, Deleuze JF, Tost J (2018)
    Enrichment of methylated molecules using enhanced-ice-co-amplification at lower denaturation temperature-PCR (E-ice-COLD-PCR) for the sensitive detection of disease-related hypermethylation
    Epigenomics, 10 (5), 525-537
    DOI 10.2217/epi-2017-0166, PubMed 29697281
  21. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW et al. (2018)
    Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
    Am J Hum Genet, 104 (1), 21-34
    DOI 10.1016/j.ajhg.2018.11.002, PubMed 30554720
  22. Nguyen CB, Kumar S, Zucknick M, Kristensen VN, Gjerstad J, Nilsen H, Wyller VB (2018)
    Associations between clinical symptoms, plasma norepinephrine and deregulated immune gene networks in subgroups of adolescent with Chronic Fatigue Syndrome
    Brain Behav Immun, 76, 82-96
    DOI 10.1016/j.bbi.2018.11.008, PubMed 30419269
  23. Norum JH, Skarpen E, Brech A, Kuiper R, Waaler J, Krauss S, Sørlie T (2018)
    The tankyrase inhibitor G007-LK inhibits small intestine LGR5+ stem cell proliferation without altering tissue morphology
    Biol Res, 51 (1), 3
    DOI 10.1186/s40659-017-0151-6, PubMed 29316982
  24. Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J (2018)
    Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
    Ann Oncol, 29 (6), 1409-1416
    DOI 10.1093/annonc/mdy121, PubMed 29668860
  25. O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, Brauch H, Brenner H, Brinton L, Buchanan DD, Burwinkel B, Chang-Claude J, Chanock SJ, Chen C, Chen MM, Cheng THT, Clarke CL, Clendenning M, Cook LS, Couch FJ, Cox A et al. (2018)
    Identification of nine new susceptibility loci for endometrial cancer
    Nat Commun, 9 (1), 3166
    DOI 10.1038/s41467-018-05427-7, PubMed 30093612
  26. Painter JN, O'Mara TA, Morris AP, Cheng THT, Gorman M, Martin L, Hodson S, Jones A, Martin NG, Gordon S, Henders AK, Attia J, McEvoy M, Holliday EG, Scott RJ, Webb PM, Fasching PA, Beckmann MW, Ekici AB, Hein A, Rübner M, Hall P, Czene K, Dörk T, Dürst M et al. (2018)
    Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses
    Cancer Med, 7 (5), 1978-1987
    DOI 10.1002/cam4.1445, PubMed 29608257
  27. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
    Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
    Mol Oncol, 12 (9), 1540-1558
    DOI 10.1002/1878-0261.12319, PubMed 29741811
  28. Risberg B, Tsui DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass F, Chandrananda D, Moore E, Morris J, Plagnol V, Rosenfeld N, Caldas C, Brenton JD, Gale D (2018)
    Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients
    J Mol Diagn, 20 (6), 883-892
    DOI 10.1016/j.jmoldx.2018.07.005, PubMed 30165204
  29. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
    Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
    Mol Oncol, 12 (11), 1838-1855
    DOI 10.1002/1878-0261.12375, PubMed 30133130
  30. Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC (2018)
    A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
    Mol Oncol, 12 (6), 913-924
    DOI 10.1002/1878-0261.12204, PubMed 29656435
  31. Sugiaman-Trapman D, Vitezic M, Jouhilahti EM, Mathelier A, Lauter G, Misra S, Daub CO, Kere J, Swoboda P (2018)
    Characterization of the human RFX transcription factor family by regulatory and target gene analysis
    BMC Genomics, 19 (1), 181
    DOI 10.1186/s12864-018-4564-6, PubMed 29510665
  32. Tahiri A, Aure MR, Kristensen VN (2018)
    MicroRNA Networks in Breast Cancer Cells
    Methods Mol Biol, 1711, 55-81
    DOI 10.1007/978-1-4939-7493-1_4, PubMed 29344885
  33. Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
    N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
    Mol Oncol, 12 (6), 972-990
    DOI 10.1002/1878-0261.12312, PubMed 29698574
  34. Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
    Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
    Br J Cancer, 118 (12), 1609-1616
    DOI 10.1038/s41416-018-0115-9, PubMed 29872151
  35. Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
    Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
    J Thromb Haemost, 16 (7), 1347-1356
    DOI 10.1111/jth.14151, PubMed 29766637
  36. Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
    Sample-Index Misassignment Impacts Tumour Exome Sequencing
    Sci Rep, 8 (1), 5307
    DOI 10.1038/s41598-018-23563-4, PubMed 29593270
  37. Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC (2018)
    Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
    Clin Epigenetics, 10, 41
    DOI 10.1186/s13148-018-0474-3, PubMed 29619118
  38. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M et al. (2018)
    A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
    Nat Genet, 50 (7), 968-978
    DOI 10.1038/s41588-018-0132-x, PubMed 29915430

Publications 2017

  1. Abravan A, Eide HA, Knudtsen IS, Løndalen AM, Helland Å, Malinen E (2017)
    Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
    Clin Transl Radiat Oncol, 4, 57-63
    DOI 10.1016/j.ctro.2017.04.002, PubMed 29594209
  2. Abravan A, Knudtsen IS, Eide HA, Løndalen AM, Helland Å, van Luijk P, Malinen E (2017)
    A new method to assess pulmonary changes using 18F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy
    Acta Oncol, 56 (11), 1597-1603
    DOI 10.1080/0284186X.2017.1349336, PubMed 28849707
  3. Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S (2017)
    AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
    Mol Cancer Ther, 17 (1), 254-263
    DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988
  4. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
    Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
    Breast Cancer Res, 19 (1), 44
    DOI 10.1186/s13058-017-0812-y, PubMed 28356166
  5. Bjørklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnæs GIG, Toppmeyer D, Riis M, Naume B, Børresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G (2017)
    Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
    Sci Rep, 7 (1), 5568
    DOI 10.1038/s41598-017-05537-0, PubMed 28717182
  6. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
    Interrogating open issues in cancer precision medicine with patient-derived xenografts
    Nat Rev Cancer, 17 (4), 254-268
    DOI 10.1038/nrc.2016.140, PubMed 28104906
  7. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
    Interrogating open issues in cancer medicine with patient-derived xenografts
    Nat Rev Cancer, 17 (10), 632 (in press)
    DOI 10.1038/nrc.2017.85, PubMed 28912576
  8. Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2017)
    Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
    Nat Commun, 8 (1), 1221
    DOI 10.1038/s41467-017-01355-0, PubMed 29089486
  9. Clancy T, Dannenfelser R, Troyanskaya O, Malmberg KJ, Hovig E, Kristensen V (2017)
    Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
    Curr Pharm Des, 23 (32), 4716-4725
    DOI 10.2174/1381612823666170710154936, PubMed 28699527
  10. Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
    A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
    Thromb Res, 157, 111-116
    DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
  11. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
    Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
    Oncotarget, 8 (34), 57121-57133
    DOI 10.18632/oncotarget.19078, PubMed 28915659
  12. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C et al. (2017)
    HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
    Nat Med, 23 (4), 517-525
    DOI 10.1038/nm.4292, PubMed 28288110
  13. Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL, Børresen-Dale AL, Thompson A, Eyfjord JE, Kong G, Stratton MR, Nik-Zainal S (2017)
    Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
    Cancer Res, 77 (18), 4755-4762
    DOI 10.1158/0008-5472.CAN-17-1083, PubMed 28904067
  14. Dumeaux V, Fjukstad B, Fjosne HE, Frantzen JO, Holmen MM, Rodegerdts E, Schlichting E, Børresen-Dale AL, Bongo LA, Lund E, Hallett M (2017)
    Interactions between the tumor and the blood systemic response of breast cancer patients
    PLoS Comput Biol, 13 (9), e1005680
    DOI 10.1371/journal.pcbi.1005680, PubMed 28957325
  15. Ellingjord-Dale M, Vos L, Hjerkind KV, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G (2017)
    Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program
    Cancer Epidemiol Biomarkers Prev, 26 (12), 1736-1744
    DOI 10.1158/1055-9965.EPI-17-0611, PubMed 28877889
  16. Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
    Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
    Metabolomics, 13 (4), 37
    DOI 10.1007/s11306-017-1168-0
  17. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
    DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
    Oncotarget, 8 (1), 1074-1082
    DOI 10.18632/oncotarget.13718, PubMed 27911866
  18. Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
    DNA methylation at enhancers identifies distinct breast cancer lineages
    Nat Commun, 8 (1), 1379
    DOI 10.1038/s41467-017-00510-x, PubMed 29123100
  19. Fosdahl AM, Dietrich M, Schink KO, Malik MS, Skeie M, Bertelsen V, Stang E (2017)
    ErbB3 interacts with Hrs and is sorted to lysosomes for degradation
    Biochim Biophys Acta Mol Cell Res, 1864 (12), 2241-2252
    DOI 10.1016/j.bbamcr.2017.08.011, PubMed 28867611
  20. Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K et al. (2017)
    Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
    Cancer Discov, 7 (10), 1098-1115
    DOI 10.1158/2159-8290.CD-17-0222, PubMed 28652380
  21. Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Viari A et al. (2017)
    A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
    Nat Genet, 49 (3), 341-348
    DOI 10.1038/ng.3771, PubMed 28112740
  22. Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Viari A et al. (2017)
    Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
    Nat Genet, 49 (11), 1661
    DOI 10.1038/ng1117-1661a, PubMed 29074948
  23. Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, Aittomäki K, Andrulis IL, Apicella C, Arndt V, Barrdahl M, Benitez J, Berg CD, Blomqvist C, Bojesen SE, Bonanni B, Brand JS, Brenner H, Broeks A, Burwinkel B, Caldas C, Campa D, Canzian F, Chang-Claude J et al. (2017)
    Body mass index and breast cancer survival: a Mendelian randomization analysis
    Int J Epidemiol, 46 (6), 1814-1822
    DOI 10.1093/ije/dyx131, PubMed 29232439
  24. Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
    Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
    Br J Cancer, 116 (10), 1271-1278
    DOI 10.1038/bjc.2017.93, PubMed 28399112
  25. Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C (2017)
    HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
    Br J Cancer, 118 (3), 378-387
    DOI 10.1038/bjc.2017.422, PubMed 29169184
  26. Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
    Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
    Dis Markers, 2017, 3098542
    DOI 10.1155/2017/3098542, PubMed 28293063
  27. Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017)
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
    Breast Cancer Res, 19 (1), 125
    DOI 10.1186/s13058-017-0916-4, PubMed 29183390
  28. Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
    Int J Cancer, 141 (1), 184-190
    DOI 10.1002/ijc.30726, PubMed 28387924
  29. Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
    Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
    Breast Cancer (Dove Med Press), 9, 185-198
    DOI 10.2147/BCTT.S115600, PubMed 28356768
  30. Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, Maguire P, Kremeyer B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN et al. (2017)
    PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1
    Oncotarget, 8 (61), 102769-102782
    DOI 10.18632/oncotarget.21800, PubMed 29262523
  31. Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A et al. (2017)
    Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
    Nature, 543 (7647), 714-718
    DOI 10.1038/nature21703, PubMed 28329761
  32. Khan A, Mathelier A (2017)
    Intervene: a tool for intersection and visualization of multiple gene or genomic region sets
    BMC Bioinformatics, 18 (1), 287
    DOI 10.1186/s12859-017-1708-7, PubMed 28569135
  33. Kristensen VN (2017)
    The Antigenicity of the Tumor Cell - Context Matters
    N Engl J Med, 376 (5), 491-493
    DOI 10.1056/NEJMcibr1613793, PubMed 28146670
  34. Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU (2017)
    Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials
    Acta Oncol, 57 (1), 38-43
    DOI 10.1080/0284186X.2017.1401735, PubMed 29172851
  35. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN et al. (2017)
    Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
    Cancer Res, 77 (6), 1250-1260
    DOI 10.1158/0008-5472.CAN-16-2179, PubMed 28254861
  36. McGowan M, Kleinberg L, Halvorsen AR, Helland Å, Brustugun OT (2017)
    NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
    Genes Cancer, 8 (3-4), 497-504
    DOI 10.18632/genesandcancer.136, PubMed 28680534
  37. Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A (2017)
    Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
    Virchows Arch, 472 (3), 395-405
    DOI 10.1007/s00428-017-2263-3, PubMed 29134439
  38. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M et al. (2017)
    Association analysis identifies 65 new breast cancer risk loci
    Nature, 551 (7678), 92-94
    DOI 10.1038/nature24284, PubMed 29059683
  39. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM, ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F et al. (2017)
    Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
    Nat Genet, 49 (12), 1767-1778
    DOI 10.1038/ng.3785, PubMed 29058716
  40. Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Breast Cancer Res, 19 (1), 120
    DOI 10.1186/s13058-017-0911-9, PubMed 29137653
  41. Quigley DA, Tahiri A, Lüders T, Riis MH, Balmain A, Børresen-Dale AL, Bukholm I, Kristensen V (2017)
    Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue
    Oncoimmunology, 6 (11), e1356142
    DOI 10.1080/2162402X.2017.1356142, PubMed 29147603
  42. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
  43. Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C (2017)
    Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
    Am J Pathol, 187 (10), 2152-2162
    DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194
  44. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
    Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
    Mol Oncol, 11 (10), 1361-1379
    DOI 10.1002/1878-0261.12105, PubMed 28657165
  45. Samuel N, Id Said B, Guha T, Novokmet A, Li W, Silwal-Pandit L, Børrsen-Dale AL, Langerød A, Hudson TJ, Malkin D (2017)
    Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk
    Hum Mutat, 38 (3), 265-268
    DOI 10.1002/humu.23154, PubMed 27957778
  46. Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P et al. (2017)
    BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
    Cancer Res, 77 (11), 2789-2799
    DOI 10.1158/0008-5472.CAN-16-2568, PubMed 28283652
  47. Silwal-Pandit L, Langerød A, Børresen-Dale AL (2017)
    TP53 Mutations in Breast and Ovarian Cancer
    Cold Spring Harb Perspect Med, 7 (1)
    DOI 10.1101/cshperspect.a026252, PubMed 27815305
  48. Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
    The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
    Clin Cancer Res, 23 (16), 4662-4670
    DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
  49. Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
    Eur J Cancer, 81, 26-35
    DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137
  50. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
    Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
    Oncotarget, 8 (44), 76290-76304
    DOI 10.18632/oncotarget.19350, PubMed 29100312

Publications 2016

  1. Brustugun OT, Sprauten M, Helland Å (2016)
    Real-world data on nivolumab treatment of non-small cell lung cancer
    Acta Oncol, 56 (3), 438-440
    DOI 10.1080/0284186X.2016.1253865, PubMed 27892773
  2. Børnich C, Grytten I, Hovig E, Paulsen J, Čech M, Sandve GK (2016)
    Galaxy Portal: interacting with the galaxy platform through mobile devices
    Bioinformatics, 32 (11), 1743-5
    DOI 10.1093/bioinformatics/btw042, PubMed 26819474
  3. Cheng TH, Thompson DJ, O'Mara TA, Painter JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church D, Gorman M, Martin L, National Study of Endometrial Cancer Genetics Group (NSECG), Hodgson S, Webb PM, Australian National Endometrial Cancer Study Group (ANECS), Attia J, Holliday EG, McEvoy M, Scott RJ, Henders AK, Martin NG, Montgomery GW, Nyholt DR, Ahmed S et al. (2016)
    Five endometrial cancer risk loci identified through genome-wide association analysis
    Nat Genet, 48 (6), 667-674
    DOI 10.1038/ng.3562, PubMed 27135401
  4. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C et al. (2016)
    Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
    Nat Commun, 7, 11375
    DOI 10.1038/ncomms11375, PubMed 27117709
  5. Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
    Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
    Nature, 537 (7621), 548-552
    DOI 10.1038/nature19360, PubMed 27626377
  6. Darabi H, Beesley J, Droit A, Kar S, Nord S, Moradi Marjaneh M, Soucy P, Michailidou K, Ghoussaini M, Fues Wahl H, Bolla MK, Wang Q, Dennis J, Alonso MR, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Broeks A, Brüning T et al. (2016)
    Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)
    Sci Rep, 6, 32512
    DOI 10.1038/srep32512, PubMed 27600471
  7. Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B (2016)
    Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
    Genome Biol, 17 (1), 250
    DOI 10.1186/s13059-016-1109-7, PubMed 27931250
  8. Dominguez-Valentin M, Gras Navarro A, Rahman AM, Kumar S, Retière C, Ulvestad E, Kristensen V, Lund-Johansen M, Lie BA, Enger PØ, Njølstad G, Kristoffersen E, Lie SA, Chekenya M (2016)
    Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients
    Cancer Res, 76 (18), 5326-36
    DOI 10.1158/0008-5472.CAN-16-1162, PubMed 27406829
  9. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
    Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
    Nat Genet, 48 (4), 374-86
    DOI 10.1038/ng.3521, PubMed 26928228
  10. Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, Wang Q, Dennis J, Ahmad J, Thompson ER, Damiola F, Pertesi M, Voegele C, Mebirouk N, Robinot N, Durand G, Forey N, Luben RN, Ahmed S, Aittomäki K, Anton-Culver H et al. (2016)
    No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing
    J Med Genet, 53 (5), 298-309
    DOI 10.1136/jmedgenet-2015-103529, PubMed 26921362
  11. Eftang LL, Klajic J, Kristensen VN, Tost J, Esbensen QY, Blom GP, Bukholm IR, Bukholm G (2016)
    GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer
    BMC Cancer, 16, 225
    DOI 10.1186/s12885-016-2247-8, PubMed 26984265
  12. Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
    The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
    BMC Cancer, 16, 71
    DOI 10.1186/s12885-016-2104-9, PubMed 26858029
  13. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
    Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
    Clin Transl Immunology, 5 (11), e109
    DOI 10.1038/cti.2016.65, PubMed 27990285
  14. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
    Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
    Oncoimmunology, 5 (12), e1248015
    DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
  15. Fiorito E, Sharma Y, Gilfillan S, Wang S, Singh SK, Satheesh SV, Katika MR, Urbanucci A, Thiede B, Mills IG, Hurtado A (2016)
    CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions
    Nucleic Acids Res, 44 (22), 10588-10602
    DOI 10.1093/nar/gkw785, PubMed 27638884
  16. Ghoussaini M, French JD, Michailidou K, Nord S, Beesley J, Canisus S, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Dennis J, Bolla MK, Wang Q, Dicks E, Milne RL, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O et al. (2016)
    Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
    Am J Hum Genet, 99 (4), 903-911
    DOI 10.1016/j.ajhg.2016.07.017, PubMed 27640304
  17. Guo Y, Warren Andersen S, Shu XO, Michailidou K, Bolla MK, Wang Q, Garcia-Closas M, Milne RL, Schmidt MK, Chang-Claude J, Dunning A, Bojesen SE, Ahsan H, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bogdanova NV, Bonanni B, Børresen-Dale AL, Brand J, Brauch H et al. (2016)
    Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
    PLoS Med, 13 (8), e1002105
    DOI 10.1371/journal.pmed.1002105, PubMed 27551723
  18. Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
    A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
    Oncotarget, 7 (24), 37250-37259
    DOI 10.18632/oncotarget.9363, PubMed 27191990
  19. Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
    Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
    Mol Oncol, 11 (2), 220-234
    DOI 10.1002/1878-0261.12025, PubMed 28145100
  20. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
    TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
    Front Genet, 7, 85
    DOI 10.3389/fgene.2016.00085, PubMed 27242894
  21. Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, Baynes C, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, NBCS Collaborators, Couch FJ et al. (2016)
    Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21
    Oncotarget, 7 (49), 80140-80163
    DOI 10.18632/oncotarget.12818, PubMed 27792995
  22. Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B et al. (2016)
    Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3
    Breast Cancer Res Treat, 161 (1), 117-134
    DOI 10.1007/s10549-016-4018-2, PubMed 27796716
  23. Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF, Oslo Breast Cancer Consortium (OSBREAC) (2016)
    Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
    Cancer Metab, 4, 12
    DOI 10.1186/s40170-016-0152-x, PubMed 27350877
  24. Helland A (2016)
    MicroRNA-profiles in lung adenocarcinomas
    Expert Rev. Precis. Med. Drug Dev., 1 (5), 469-474
    DOI 10.1080/23808993.2016.1240011
  25. Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T et al. (2016)
    Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
    PLoS One, 11 (8), e0160316
    DOI 10.1371/journal.pone.0160316, PubMed 27556229
  26. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
    Subtype-specific micro-RNA expression signatures in breast cancer progression
    Int J Cancer, 139 (5), 1117-28
    DOI 10.1002/ijc.30142, PubMed 27082076
  27. Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
    Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
    F1000Res, 5, 38
    DOI 10.12688/f1000research.7599.1, PubMed 27081474
  28. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ, ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH et al. (2016)
    Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types
    Cancer Discov, 6 (9), 1052-67
    DOI 10.1158/2159-8290.CD-15-1227, PubMed 27432226
  29. Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, Kristensen VN, Solvang HK (2016)
    A systematic comparison of copy number alterations in four types of female cancer
    BMC Cancer, 16 (1), 913
    DOI 10.1186/s12885-016-2899-4, PubMed 27876019
  30. Kleibl Z, Kristensen VN (2016)
    Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management
    Breast, 28, 136-44
    DOI 10.1016/j.breast.2016.05.006, PubMed 27318168
  31. Kongsgaard A, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    Diagn Pathol, 11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
  32. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M et al. (2016)
    Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
    Nat Commun, 7, 12675
    DOI 10.1038/ncomms12675, PubMed 27601076
  33. Lesurf R, Aure MR, Mørk HH, Vitelli V, Oslo Breast Cancer Research Consortium (OSBREAC), Lundgren S, Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M, Sørlie T (2016)
    Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer
    Cell Rep, 16 (4), 1166-1179
    DOI 10.1016/j.celrep.2016.06.051, PubMed 27396337
  34. Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F (2016)
    STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
    Oncotarget, 8 (54), 91817-91827
    DOI 10.18632/oncotarget.11131, PubMed 29190878
  35. Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY et al. (2016)
    rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk
    Sci Rep, 6, 36874
    DOI 10.1038/srep36874, PubMed 27845421
  36. Lizio M, Harshbarger J, Abugessaisa I, Noguchi S, Kondo A, Severin J, Mungall C, Arenillas D, Mathelier A, Medvedeva YA, Lennartsson A, Drabløs F, Ramilowski JA, Rackham O, Gough J, Andersson R, Sandelin A, Ienasescu H, Ono H, Bono H, Hayashizaki Y, Carninci P, Forrest AR, Kasukawa T, Kawaji H (2016)
    Update of the FANTOM web resource: high resolution transcriptome of diverse cell types in mammals
    Nucleic Acids Res, 45 (D1), D737-D743
    DOI 10.1093/nar/gkw995, PubMed 27794045
  37. Mathelier A, Xin B, Chiu TP, Yang L, Rohs R, Wasserman WW (2016)
    DNA Shape Features Improve Transcription Factor Binding Site Predictions In Vivo
    Cell Syst, 3 (3), 278-286.e4
    DOI 10.1016/j.cels.2016.07.001, PubMed 27546793
  38. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
    Lung Cancer, 103, 52-57
    DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
  39. Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
    Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
    Oncotarget, 7 (27), 41948-41958
    DOI 10.18632/oncotarget.9632, PubMed 27248825
  40. Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL et al. (2016)
    The topography of mutational processes in breast cancer genomes
    Nat Commun, 7, 11383
    DOI 10.1038/ncomms11383, PubMed 27136393
  41. Muranen TA, Greco D, Blomqvist C, Aittomäki K, Khan S, Hogervorst F, Verhoef S, Pharoah PDP, Dunning AM, Shah M, Luben R, Bojesen SE, Nordestgaard BG, Schoemaker M, Swerdlow A, García-Closas M, Figueroa J, Dörk T, Bogdanova NV, Hall P, Li J, Khusnutdinova E, Bermisheva M, Kristensen V, Borresen-Dale AL et al. (2016)
    Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
    Genet Med, 19 (5), 599-603
    DOI 10.1038/gim.2016.147, PubMed 27711073
  42. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C et al. (2016)
    Landscape of somatic mutations in 560 breast cancer whole-genome sequences
    Nature, 534 (7605), 47-54
    DOI 10.1038/nature17676, PubMed 27135926
  43. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
    Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
    Oncotarget, 7 (6), 6891-901
    DOI 10.18632/oncotarget.6902, PubMed 26771843
  44. Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M, Scott RJ, Ahmed S, Healey CS, Shah M, Gorman M, Martin L, Hodgson SV, Beckmann MW, Ekici AB, Fasching PA, Hein A, Rübner M, Czene K, Darabi H, Hall P et al. (2016)
    Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer
    Cancer Epidemiol Biomarkers Prev, 25 (11), 1503-1510
    DOI 10.1158/1055-9965.EPI-16-0147, PubMed 27550749
  45. Papp J, Kovacs ME, Matrai Z, Orosz E, Kásler M, Børresen-Dale AL, Olah E (2016)
    Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary
    Fam Cancer, 15 (1), 85-97
    DOI 10.1007/s10689-015-9845-5, PubMed 26446593
  46. Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, Ranta S, Schleutker J, Winqvist R, Kallioniemi A, Dörk T, Bogdanova NV, Figueroa J, Pharoah PD, Schmidt MK, Dunning AM, García-Closas M, Bolla MK, Dennis J, Michailidou K, Wang Q, Hopper JL, Southey MC, Rosenberg EH, Fasching PA et al. (2016)
    RAD51B in Familial Breast Cancer
    PLoS One, 11 (5), e0153788
    DOI 10.1371/journal.pone.0153788, PubMed 27149063
  47. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR et al. (2016)
    The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
    Nat Commun, 7, 11479
    DOI 10.1038/ncomms11479, PubMed 27161491
  48. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J et al. (2016)
    Genetic predisposition to ductal carcinoma in situ of the breast
    Breast Cancer Res, 18 (1), 22
    DOI 10.1186/s13058-016-0675-7, PubMed 26884359
  49. Quigley DA, Kandyba E, Huang P, Halliwill KD, Sjölund J, Pelorosso F, Wong CE, Hirst GL, Wu D, Delrosario R, Kumar A, Balmain A (2016)
    Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer
    Cell Rep, 16 (4), 1153-1165
    DOI 10.1016/j.celrep.2016.06.061, PubMed 27425619
  50. Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE (2016)
    Fatigue During and After Breast Cancer Therapy-A Prospective Study
    J Pain Symptom Manage, 53 (3), 551-560
    DOI 10.1016/j.jpainsymman.2016.09.011, PubMed 28042070
  51. Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD (2016)
    Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
    J Transl Med, 14 (1), 295
    DOI 10.1186/s12967-016-1059-6, PubMed 27756323
  52. Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, Lægreid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN (2016)
    Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein
    Kidney Int Rep, 2 (3), 461-469
    DOI 10.1016/j.ekir.2016.11.005, PubMed 29142973
  53. Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
    The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
    Cancer Res, 76 (17), 5092-102
    DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
  54. Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F, Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt, Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y (2016)
    LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
    EMBO Mol Med, 8 (9), 1052-64
    DOI 10.15252/emmm.201606198, PubMed 27485121
  55. Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, Waisfisz Q, Hollestelle A, Schutte M, van den Ouweland A, Hooning M, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Arndt V, Bermisheva M, Bogdanova NV, Bolla MK, Brauch H, Brenner H, Brüning T, Burwinkel B, Chang-Claude J et al. (2016)
    Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
    J Clin Oncol, 34 (23), 2750-60
    DOI 10.1200/JCO.2016.66.5844, PubMed 27269948
  56. Shi J, Zhang Y, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao Z, Guo X, Benitez J, Beeghly-Fadiel A, Blot W, Bogdanova NV, Bojesen SE, Brauch H et al. (2016)
    Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
    Int J Cancer, 139 (6), 1303-1317
    DOI 10.1002/ijc.30150, PubMed 27087578
  57. Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S, Dronov S, Mamanova L, Rosic A, Ju YS, Cooke SL, Ramakrishna M, Papaemmanuil E, Davies HR, Tarpey PS, Van Loo P, Wedge DC, Jones DR, Martin S, Marshall J, Anderson E, Hardy C, ICGC Breast Cancer Working Group, Oslo Breast Cancer Research Consortium, Barbashina V, Aparicio SA, Sauer T et al. (2016)
    Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
    Cell Rep, 16 (7), 2032-46
    DOI 10.1016/j.celrep.2016.07.028, PubMed 27498871
  58. Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C et al. (2016)
    Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
    Nat Commun, 7, 12910
    DOI 10.1038/ncomms12910, PubMed 27666519
  59. Solvang HK, Frigessi A, Kaveh F, Riis ML, Lüders T, Bukholm IR, Kristensen VN, Andreassen BK (2016)
    Gene expression analysis supports tumor threshold over 2.0 cm for T-category breast cancer
    EURASIP J Bioinform Syst Biol, 2016 (1), 6
    DOI 10.1186/s13637-015-0034-5, PubMed 26900390
  60. Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A et al. (2016)
    PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
    J Med Genet, 53 (12), 800-811
    DOI 10.1136/jmedgenet-2016-103839, PubMed 27595995
  61. Sørlie T (2016)
    The Impact of Gene Expression Patterns in Breast Cancer
    Clin Chem, 62 (8), 1150-1
    DOI 10.1373/clinchem.2015.253229, PubMed 27022070
  62. Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
    TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
    Oncotarget, 7 (37), 59441-59457
    DOI 10.18632/oncotarget.11118, PubMed 27509063
  63. Tekpli X, Skaug V, Bæra R, Phillips DH, Haugen A, Mollerup S (2016)
    Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report
    Cell Oncol (Dordr), 39 (6), 583-589
    DOI 10.1007/s13402-016-0295-3, PubMed 27572263
  64. Tekpli X, Urbanucci A, Hashim A, Vågbø CB, Lyle R, Kringen MK, Staff AC, Dybedal I, Mills IG, Klungland A, Staerk J (2016)
    Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
    Epigenetics Chromatin, 9, 21
    DOI 10.1186/s13072-016-0070-8, PubMed 27252783
  65. Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, Ghesquière B, Van Dyck L, Boeckx B, Schoonjans L, Hermans E, Amant F, Kristensen VN, Peng Koh K, Mazzone M, Coleman M, Carell T, Carmeliet P, Lambrechts D (2016)
    Tumour hypoxia causes DNA hypermethylation by reducing TET activity
    Nature, 537 (7618), 63-68
    DOI 10.1038/nature19081, PubMed 27533040
  66. Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
    Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    Oncotarget, 7 (46), 75013-75022
    DOI 10.18632/oncotarget.12601, PubMed 27738330
  67. Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
    Determinants of acquired activated protein C resistance and D-dimer in breast cancer
    Thromb Res, 145, 78-83
    DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249
  68. Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
    Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
    Nat Genet, 49 (1), 65-74
    DOI 10.1038/ng.3722, PubMed 27869826
  69. Wyszynski A, Hong CC, Lam K, Michailidou K, Lytle C, Yao S, Zhang Y, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P et al. (2016)
    An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression
    Hum Mol Genet, 25 (17), 3863-3876
    DOI 10.1093/hmg/ddw223, PubMed 27402876
  70. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F et al. (2016)
    Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
    Breast Cancer Res, 18 (1), 64
    DOI 10.1186/s13058-016-0718-0, PubMed 27459855
  71. Zhao Z, Wen W, Michailidou K, Bolla MK, Wang Q, Zhang B, Long J, Shu XO, Schmidt MK, Milne RL, García-Closas M, Chang-Claude J, Lindstrom S, Bojesen SE, Ahsan H, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Blomqvist C, Bogdanova NV, Børresen-Dale AL et al. (2016)
    Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
    Cancer Causes Control, 27 (5), 679-93
    DOI 10.1007/s10552-016-0741-6, PubMed 27053251
  72. Zänker KS, Borresen-Dale AL, Huber HP (2016)
    Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy
    Biomed Hub, 1 (3), 1-9
    DOI 10.1159/000453253, PubMed 31988890

Publications 2015

  1. Alnaes GI, Ronneberg JA, Kristensen VN, Tost J (2015)
    Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer
    Genes (Basel), 6 (3), 878-900
    DOI 10.3390/genes6030878, PubMed 26393654
  2. Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U (2015)
    High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence
    PLoS One, 10 (3), e0119255
    DOI 10.1371/journal.pone.0119255, PubMed 25793771
  3. Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R, Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN (2015)
    Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
    Genome Med, 7 (1), 21
    DOI 10.1186/s13073-015-0135-5, PubMed 25873999
  4. Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ (2015)
    Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma
    HPB (Oxford), 18 (3), 247-54
    DOI 10.1016/j.hpb.2015.09.004, PubMed 27017164
  5. Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
    EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
    Acta Oncol, 55 (2), 149-55
    DOI 10.3109/0284186X.2015.1062537, PubMed 26313507
  6. Bjørklund SS, Kristensen VN, Seiler M, Kumar S, Alnæs GI, Ming Y, Kerrigan J, Naume B, Sachidanandam R, Bhanot G, Børresen-Dale AL, Ganesan S (2015)
    Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
    BMC Cancer, 15, 524
    DOI 10.1186/s12885-015-1510-8, PubMed 26183823
  7. Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
    Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
    Mol Oncol, 10 (2), 330-43
    DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
  8. Borge KS, Nord S, Van Loo P, Lingjærde OC, Gunnes G, Alnæs GI, Solvang HK, Lüders T, Kristensen VN, Børresen-Dale AL, Lingaas F (2015)
    Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN
    PLoS One, 10 (5), e0126371
    DOI 10.1371/journal.pone.0126371, PubMed 25955013
  9. Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, Blomqvist C, Butt S, Wärnberg F (2015)
    The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
    BMC Cancer, 15, 468
    DOI 10.1186/s12885-015-1479-3, PubMed 26062614
  10. Cheng TH, Thompson D, Painter J, O'Mara T, Gorman M, Martin L, Palles C, Jones A, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Giles GG, Pharoah P, Peto J, Cox A, Swerdlow A, Couch F, Cunningham JM et al. (2015)
    Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1
    Sci Rep, 5, 17369
    DOI 10.1038/srep17369, PubMed 26621817
  11. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH et al. (2015)
    Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
    Nat Cell Biol, 17 (6), 816-26
    DOI 10.1038/ncb3169, PubMed 25985394
  12. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
    Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
    Am J Hum Genet, 97 (1), 22-34
    DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
  13. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B, Esko T, Johnson AD, Elks CE, Franceschini N, He C, Altmaier E, Brody JA, Franke LL, Huffman JE, Keller MF, McArdle PF, Nutile T, Porcu E, Robino A, Rose LM et al. (2015)
    Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
    Nat Genet, 47 (11), 1294-1303
    DOI 10.1038/ng.3412, PubMed 26414677
  14. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B, Esko T, Johnson AD, Elks CE, Franceschini N, He C, Altmaier E, Brody JA, Franke LL, Huffman JE, Keller MF, McArdle PF, Nutile T, Porcu E, Robino A, Rose LM et al. (2015)
    Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair EDITORIAL COMMENT
    Obstet. Gynecol. Surv., 70 (12), 758-762
    DOI 10.1097/01.ogx.0000473766.71624.99
  15. Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM (2015)
    Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
    Ann Oncol, 27 (2), 225-32
    DOI 10.1093/annonc/mdv560, PubMed 26578726
  16. Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AF, Alnæs GI, Børresen-Dale AL, Kristensen VN, Goding CR, Jochemsen AG, Edvardsen H, Bond GL (2015)
    Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer
    Cancer Res, 75 (4), 698-708
    DOI 10.1158/0008-5472.CAN-14-2637, PubMed 25649770
  17. Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Kar S, Beesley J, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, Bojesen SE, Nordestgaard BG, Nielsen SF et al. (2015)
    Identification of novel genetic markers of breast cancer survival
    J Natl Cancer Inst, 107 (5)
    DOI 10.1093/jnci/djv081, PubMed 25890600
  18. Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Milne RL, Shu XO, Cai Q, Beesley J, Kar SP, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Blot W, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A et al. (2015)
    Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
    Cancer Epidemiol Biomarkers Prev, 24 (11), 1680-91
    DOI 10.1158/1055-9965.EPI-15-0363, PubMed 26354892
  19. Győrffy B, Bottai G, Fleischer T, Munkácsy G, Budczies J, Paladini L, Børresen-Dale AL, Kristensen VN, Santarpia L (2015)
    Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
    Int J Cancer, 138 (1), 87-97
    DOI 10.1002/ijc.29684, PubMed 26174627
  20. Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH (2015)
    Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma
    J Proteome Res, 14 (12), 5144-56
    DOI 10.1021/acs.jproteome.5b00395, PubMed 26515733
  21. Helland A (2015)
    Gene jockeys Life science and the rise of biotech enterprise.
    Tidsskr. Nor. Laegeforen., 135 (4), 356
    DOI 10.4045/tidsskr.14.1367
  22. Helland A (2015)
    Cancer stem cells
    Tidsskr. Nor. Laegeforen., 135 (8), 783
    DOI 10.4045/tidsskr.15.0031
  23. Helland A (2015)
    Viruses and human cancer
    Tidsskr. Nor. Laegeforen., 135 (9), 874
    DOI 10.4045/tidsskr.15.0167
  24. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K et al. (2015)
    Tumour exosome integrins determine organotropic metastasis
    Nature, 527 (7578), 329-35
    DOI 10.1038/nature15756, PubMed 26524530
  25. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
    Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
    Mol Oncol, 10 (1), 59-72
    DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
  26. Jabeen S, Holmboe L, Alnæs GI, Andersen AM, Hall KS, Kristensen VN (2015)
    Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate
    Pharmacogenomics J, 15 (5), 385-90
    DOI 10.1038/tpj.2015.11, PubMed 25778468
  27. Johnson KC, Koestler DC, Fleischer T, Chen P, Jenson EG, Marotti JD, Onega T, Kristensen VN, Christensen BC (2015)
    DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer
    Clin Epigenetics, 7 (1), 75
    DOI 10.1186/s13148-015-0094-0, PubMed 26213588
  28. Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ et al. (2015)
    Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
    Genome Res, 25 (6), 814-24
    DOI 10.1101/gr.190470.115, PubMed 25963125
  29. Kabisch M, Lorenzo Bermejo J, Dünnebier T, Ying S, Michailidou K, Bolla MK, Wang Q, Dennis J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Peeters S, Weltens C, Couch FJ, Olson JE, Wang X, Purrington K et al. (2015)
    Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
    Carcinogenesis, 36 (2), 256-71
    DOI 10.1093/carcin/bgu326, PubMed 25586992
  30. Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH (2015)
    AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Pharmacogenomics J, 16 (3), 272-9
    DOI 10.1038/tpj.2015.54, PubMed 26261061
  31. Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP (2015)
    Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
    Acta Oncol, 55 (3), 265-77
    DOI 10.3109/0284186X.2015.1068445, PubMed 26213211
  32. Lau C, Nygård S, Fure H, Olstad OK, Holden M, Lappegård KT, Brekke OL, Espevik T, Hovig E, Mollnes TE (2015)
    CD14 and complement crosstalk and largely mediate the transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray
    PLoS One, 10 (2), e0117261
    DOI 10.1371/journal.pone.0117261, PubMed 25706641
  33. Lau C, Olstad OK, Holden M, Nygård S, Fure H, Lappegård KT, Brekke OL, Espevik T, Hovig E, Mollnes TE (2015)
    Gene expression profiling of Gram-negative bacteria-induced inflammation in human whole blood: The role of complement and CD14-mediated innate immune response
    Genom Data, 5, 176-83
    DOI 10.1016/j.gdata.2015.05.019, PubMed 26484252
  34. Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, Dunning AM, Easton DF, Wang Q, Benitez J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Fasching PA, Haeberle L, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Marmé F, Guénel P, Truong T et al. (2015)
    Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
    Hum Genet, 135 (1), 137-54
    DOI 10.1007/s00439-015-1616-8, PubMed 26621531
  35. Lei J, Rudolph A, Moysich KB, Rafiq S, Behrens S, Goode EL, Pharoah PP, Seibold P, Fasching PA, Andrulis IL, Kristensen VN, Couch FJ, Hamann U, Hooning MJ, Nevanlinna H, Eilber U, Bolla MK, Dennis J, Wang Q, Lindblom A, Mannermaa A, Lambrechts D, García-Closas M, Hall P, Chenevix-Trench G et al. (2015)
    Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
    Breast Cancer Res, 17 (1), 18
    DOI 10.1186/s13058-015-0522-2, PubMed 25849327
  36. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A et al. (2015)
    Prediction of breast cancer risk based on profiling with common genetic variants
    J Natl Cancer Inst, 107 (5)
    DOI 10.1093/jnci/djv036, PubMed 25855707
  37. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A, kConFab Investigators, James PA, Bruinsma F, Campbell IG, Australia Ovarian Cancer Study Group, Broeks A, Schmidt MK, Hogervorst FB, HEBON et al. (2015)
    BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
    J Natl Cancer Inst, 108 (2)
    DOI 10.1093/jnci/djv315, PubMed 26586665
  38. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, Perkins BJ, Czene K, Eriksson M, Darabi H, Brand JS, Bojesen SE, Nordestgaard BG, Flyger H, Nielsen SF, Rahman N, Turnbull C, BOCS, Fletcher O, Peto J, Gibson L et al. (2015)
    Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
    Nat Genet, 47 (4), 373-80
    DOI 10.1038/ng.3242, PubMed 25751625
  39. Mäki-Jouppila JH, Pruikkonen S, Tambe MB, Aure MR, Halonen T, Salmela AL, Laine L, Børresen-Dale AL, Kallio MJ (2015)
    MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase
    Mol Oncol, 9 (6), 1056-70
    DOI 10.1016/j.molonc.2015.01.005, PubMed 25682900
  40. Nielsen HM, How-Kit A, Guerin C, Castinetti F, Vollan HK, De Micco C, Daunay A, Taieb D, Van Loo P, Besse C, Kristensen VN, Hansen LL, Barlier A, Sebag F, Tost J (2015)
    Copy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors
    Endocr Relat Cancer, 22 (6), 953-67
    DOI 10.1530/ERC-15-0086, PubMed 26400872
  41. Norum JH, Bergström Å, Andersson AB, Kuiper RV, Hoelzl MA, Sørlie T, Toftgård R (2015)
    A conditional transgenic mouse line for targeted expression of the stem cell marker LGR5
    Dev Biol, 404 (2), 35-48
    DOI 10.1016/j.ydbio.2015.05.002, PubMed 26003047
  42. O'Mara TA, Glubb DM, Painter JN, Cheng T, Dennis J, Australian National Endometrial Cancer Study Group (ANECS), Attia J, Holliday EG, McEvoy M, Scott RJ, Ashton K, Proietto T, Otton G, Shah M, Ahmed S, Healey CS, Gorman M, Martin L, National Study of Endometrial Cancer Genetics Group (NSECG), Hodgson S, Fasching PA, Hein A, Beckmann MW, Ekici AB, Hall P et al. (2015)
    Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer
    Endocr Relat Cancer, 22 (5), 851-61
    DOI 10.1530/ERC-15-0319, PubMed 26330482
  43. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, Apicella C, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Hogervorst FB, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Gibson L, Aitken Z, Warren H, Sawyer E, Tomlinson I et al. (2015)
    Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2
    Hum Mol Genet, 24 (10), 2966-84
    DOI 10.1093/hmg/ddv035, PubMed 25652398
  44. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT et al. (2015)
    No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
    Gynecol Oncol, 141 (2), 386-401
    DOI 10.1016/j.ygyno.2015.04.034, PubMed 25940428
  45. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C (2015)
    Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
    Genes Dev, 29 (12), 1298-315
    DOI 10.1101/gad.263202.115, PubMed 26080815
  46. Pirie A, Guo Q, Kraft P, Canisius S, Eccles DM, Rahman N, Nevanlinna H, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, van Ongeval C, Nordestgaard BG et al. (2015)
    Common germline polymorphisms associated with breast cancer-specific survival
    Breast Cancer Res, 17 (1), 58
    DOI 10.1186/s13058-015-0570-7, PubMed 25897948
  47. Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
    Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
    Mol Oncol, 9 (4), 861-76
    DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
  48. Quigley DA, Kristensen V (2015)
    Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
    Mol Oncol, 9 (10), 2054-62
    DOI 10.1016/j.molonc.2015.10.003, PubMed 26607741
  49. Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH (2015)
    Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
    Mol Oncol, 10 (2), 303-16
    DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090
  50. Seibold P, Schmezer P, Behrens S, Michailidou K, Bolla MK, Wang Q, Flesch-Janys D, Nevanlinna H, Fagerholm R, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Wildiers H, Kristensen V, Alnæs GG, Nord S, Borresen-Dale AL, Hooning MJ, Hollestelle A, Jager A et al. (2015)
    A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
    BMC Cancer, 15, 978
    DOI 10.1186/s12885-015-1957-7, PubMed 26674097
  51. Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
    The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
    PLoS One, 10 (10), e0139965
    DOI 10.1371/journal.pone.0139965, PubMed 26460974
  52. Skrbo N, Tenstad E, Mælandsmo GM, Sørlie T, Andersen K (2015)
    From autonomy to community; new perspectives on tumorigenicity and therapy resistance
    Cancer Treat Rev, 41 (10), 809-13
    DOI 10.1016/j.ctrv.2015.10.004, PubMed 26519005
  53. Stone J, Thompson DJ, Dos Santos Silva I, Scott C, Tamimi RM, Lindstrom S, Kraft P, Hazra A, Li J, Eriksson L, Czene K, Hall P, Jensen M, Cunningham J, Olson JE, Purrington K, Couch FJ, Brown J, Leyland J, Warren RM, Luben RN, Khaw KT, Smith P, Wareham NJ, Jud SM et al. (2015)
    Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
    Cancer Res, 75 (12), 2457-67
    DOI 10.1158/0008-5472.CAN-14-2012, PubMed 25862352
  54. Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
    Targeting lung cancer through inhibition of checkpoint kinases
    Front Genet, 6, 70
    DOI 10.3389/fgene.2015.00070, PubMed 25774168
  55. Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, Doody D, Dennis J, Webb PM, Australian National Endometrial Cancer Study Group (ANECS), Gorman M, Martin L, Hodgson S, National Study of Endometrial Cancer Genetics Group (NSECG), Michailidou K, Tyrer JP, Maranian MJ, Hall P, Czene K, Darabi H, Li J, Fasching PA, Hein A, Beckmann MW, Ekici AB et al. (2015)
    CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer
    Endocr Relat Cancer, 23 (2), 77-91
    DOI 10.1530/ERC-15-0386, PubMed 26574572
  56. Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N (2015)
    Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
    Breast Cancer Res, 17 (1), 44
    DOI 10.1186/s13058-015-0548-5, PubMed 25882602
  57. Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning AM, Chang-Claude J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Wildiers H et al. (2015)
    Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
    J Natl Cancer Inst, 107 (11)
    DOI 10.1093/jnci/djv219, PubMed 26296642
  58. Aakula A, Leivonen SK, Hintsanen P, Aittokallio T, Ceder Y, Børresen-Dale AL, Perälä M, Östling P, Kallioniemi O (2015)
    MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth
    Mol Oncol, 9 (7), 1287-300
    DOI 10.1016/j.molonc.2015.03.001, PubMed 25907805

Publications 2014

  1. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
    Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
    Cell Rep, 6 (3), 514-27
    DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
  2. Askautrud HA, Gjernes E, Gunnes G, Sletten M, Ross DT, Børresen-Dale AL, Iversen N, Tranulis MA, Frengen E (2014)
    Global gene expression analysis reveals a link between NDRG1 and vesicle transport
    PLoS One, 9 (1), e87268
    DOI 10.1371/journal.pone.0087268, PubMed 24498060
  3. Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
    Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
    Int J Cancer, 135 (8), 1812-21
    DOI 10.1002/ijc.28828, PubMed 24599520
  4. Carvajal-Carmona LG, O'Mara TA, Painter JN, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Pooley K, Beesley J, Cheng T, Jones A, Howarth K, Martin L, Gorman M, Hodgson S, National Study of Endometrial Cancer Genetics Group (NSECG), Australian National Endometrial Cancer Study Group (ANECS), Wentzensen N, Fasching PA, Hein A, Beckmann MW, Renner SP et al. (2014)
    Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk
    Hum Genet, 134 (2), 231-45
    DOI 10.1007/s00439-014-1515-4, PubMed 25487306
  5. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K et al. (2014)
    Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers
    Cancer Cell, 26 (6), 863-879
    DOI 10.1016/j.ccell.2014.10.010, PubMed 25490449
  6. Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Børresen-Dale AL, Kristensen VN, Tost J (2014)
    Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients
    Int J Cancer, 134 (11), 2615-25
    DOI 10.1002/ijc.28606, PubMed 24395279
  7. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
    Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
    Genome Biol, 15 (8), 435
    DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
  8. Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE et al. (2014)
    Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
    Nat Commun, 4, 4999
    DOI 10.1038/ncomms5999, PubMed 25248036
  9. Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM, Kaufmann S, Beesley J, Canisius S, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Schmidt MK, Broeks A, Hogervorst FB, van der Schoot CE, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P et al. (2014)
    Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1
    Am J Hum Genet, 96 (1), 5-20
    DOI 10.1016/j.ajhg.2014.11.009, PubMed 25529635
  10. Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
    Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
    Breast Cancer Res, 16 (1), R5
    DOI 10.1186/bcr3597, PubMed 24447408
  11. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
    Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
    Int J Cancer, 135 (9), 2085-95
    DOI 10.1002/ijc.28862, PubMed 24658971
  12. Hongisto V, Aure MR, Mäkelä R, Sahlberg KK (2014)
    The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description
    Genom Data, 2, 249-53
    DOI 10.1016/j.gdata.2014.06.025, PubMed 26484103
  13. Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, Folkerd EJ, Haynes BP, Hopper JL, Southey MC, Dite GS, Apicella C, Schmidt MK, Broeks A, Van't Veer LJ, Atsma F, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Ekici AB, Renner SP, Sawyer E, Tomlinson I, Kerin M et al. (2014)
    Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
    Breast Cancer Res, 16 (3), R51
    DOI 10.1186/bcr3662, PubMed 24887515
  14. Khan S, Greco D, Michailidou K, Milne RL, Muranen TA, Heikkinen T, Aaltonen K, Dennis J, Bolla MK, Liu J, Hall P, Irwanto A, Humphreys K, Li J, Czene K, Chang-Claude J, Hein R, Rudolph A, Seibold P, Flesch-Janys D, Fletcher O, Peto J, dos Santos Silva I, Johnson N, Gibson L et al. (2014)
    MicroRNA related polymorphisms and breast cancer risk
    PLoS One, 9 (11), e109973
    DOI 10.1371/journal.pone.0109973, PubMed 25390939
  15. Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
    FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
    BMC Cancer, 14, 340
    DOI 10.1186/1471-2407-14-340, PubMed 24884501
  16. Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J, Kristensen VN (2014)
    DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors
    Clin Cancer Res, 20 (24), 6357-66
    DOI 10.1158/1078-0432.CCR-14-0297, PubMed 25294903
  17. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
    A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
    Clin Cancer Res, 21 (5), 1207-14
    DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
  18. Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL (2014)
    Principles and methods of integrative genomic analyses in cancer
    Nat Rev Cancer, 14 (5), 299-313
    DOI 10.1038/nrc3721, PubMed 24759209
  19. Li J, Lindström LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, Michailidou K, Dennis J, Bolla MK, Wang Q, Van 't Veer LJ, Cornelissen S, Rutgers E, Southey MC, Apicella C, Dite GS, Hopper JL, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Blomqvist C, Muranen TA, Aittomäki K, Lindblom A et al. (2014)
    2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
    Nat Commun, 5, 4051
    DOI 10.1038/ncomms5051, PubMed 24937182
  20. Lin WY, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, Hopper JL, Apicella C, Southey MC, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Th Rutgers EJ, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N et al. (2014)
    Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
    Hum Mol Genet, 24 (1), 285-98
    DOI 10.1093/hmg/ddu431, PubMed 25168388
  21. Norum JH, Andersen K, Sørlie T (2014)
    Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
    Br J Surg, 101 (8), 925-38
    DOI 10.1002/bjs.9562, PubMed 24849143
  22. Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
    Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
    Br J Cancer, 110 (8), 2072-80
    DOI 10.1038/bjc.2014.113, PubMed 24577056
  23. Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S, National Study of Endometrial Cancer Genetics Group (NSECG), CHIBCHA Consortium, De Polanco MM, Sans M et al. (2014)
    Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk
    Hum Mol Genet, 24 (5), 1478-92
    DOI 10.1093/hmg/ddu552, PubMed 25378557
  24. Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, Bojesen SE, Andrulis IL, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman CA, Fasching PA, Mannermaa A, Winqvist R, Brenner H, Lindblom A, Chenevix-Trench G, Benitez J, Swerdlow A, Kristensen V, Guénel P, Meindl A, Darabi H et al. (2014)
    Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
    Hum Mol Genet, 23 (22), 6034-46
    DOI 10.1093/hmg/ddu300, PubMed 24927736
  25. Quigley D (2014)
    RNA-seq permits a closer look at normal skin and psoriasis gene networks
    J Invest Dermatol, 134 (7), 1789-1791
    DOI 10.1038/jid.2014.66, PubMed 24924757
  26. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C, Balmain A, Børresen-Dale AL, Kristensen V (2014)
    Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53
    Mol Cancer Res, 13 (3), 493-501
    DOI 10.1158/1541-7786.MCR-14-0387, PubMed 25351767
  27. Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Børresen-Dale AL, Hackermüller J, Baumbusch LO (2014)
    Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes
    PLoS One, 9 (9), e106076
    DOI 10.1371/journal.pone.0106076, PubMed 25264628
  28. Russnes HG, Caldas C (2014)
    eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN
    EMBO Mol Med, 6 (12), 1512-4
    DOI 10.15252/emmm.201404683, PubMed 25471453
  29. Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC (2014)
    The multitude of molecular analyses in cancer: the opening of Pandora’s box
    Genome Biol, 15 (9), 447
    DOI 10.1186/s13059-014-0447-6, PubMed 25316146
  30. Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG (2014)
    Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
    Genes Chromosomes Cancer, 54 (4), 235-48
    DOI 10.1002/gcc.22237, PubMed 25546585
  31. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
    Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
    J Proteome Res, 13 (5), 2314-27
    DOI 10.1021/pr401092y, PubMed 24669823
  32. Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH (2014)
    Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
    Mol Oncol, 9 (4), 758-71
    DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086
  33. Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins KA, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC, Hopper JL, Provenzano E et al. (2014)
    Genetic predisposition to in situ and invasive lobular carcinoma of the breast
    PLoS Genet, 10 (4), e1004285
    DOI 10.1371/journal.pgen.1004285, PubMed 24743323
  34. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Langerød A (2014)
    TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance
    Clin Cancer Res, 20 (13), 3569-80
    DOI 10.1158/1078-0432.CCR-13-2943, PubMed 24803582
  35. Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
    Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
    PLoS One, 9 (11), e113278
    DOI 10.1371/journal.pone.0113278, PubMed 25419568
  36. Sternemalm J, Russnes HG, Zhao X, Risberg B, Nord S, Caldas C, Børresen-Dale AL, Stokke T, Patzke S (2014)
    Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
    Br J Cancer, 111 (2), 326-38
    DOI 10.1038/bjc.2014.297, PubMed 24901235
  37. Sørlie T, Johnsen H, Vu P, Lind GE, Lothe R, Børresen-Dale AL (2014)
    Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE)
    Methods Mol Biol, 1105, 315-24
    DOI 10.1007/978-1-62703-739-6_25, PubMed 24623239
  38. Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
    Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
    PLoS One, 9 (2), e87746
    DOI 10.1371/journal.pone.0087746, PubMed 24498368
  39. Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
    Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
    BMC Cancer, 14, 845
    DOI 10.1186/1471-2407-14-845, PubMed 25407022
  40. Tramm T, Kyndi M, Myhre S, Nord S, Alsner J, Sørensen FB, Sørlie T, Overgaard J (2014)
    Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer
    Acta Oncol, 53 (10), 1337-46
    DOI 10.3109/0284186X.2014.925580, PubMed 24957550
  41. Tramm T, Mohammed H, Myhre S, Kyndi M, Alsner J, Børresen-Dale AL, Sørlie T, Frigessi A, Overgaard J (2014)
    Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort
    Clin Cancer Res, 20 (20), 5272-80
    DOI 10.1158/1078-0432.CCR-14-0458, PubMed 25149560
  42. Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
    GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
    Genome Biol, 15 (8), 442
    DOI 10.1186/s13059-014-0442-y, PubMed 25168174
  43. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP et al. (2014)
    Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
    Science, 345 (6196), 1251343
    DOI 10.1126/science.1251343, PubMed 25082706
  44. Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH, Andersen V (2014)
    Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis
    PLoS One, 9 (8), e105254
    DOI 10.1371/journal.pone.0105254, PubMed 25166592
  45. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN, METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C (2014)
    A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer
    Mol Oncol, 9 (1), 115-27
    DOI 10.1016/j.molonc.2014.07.019, PubMed 25169931
  46. Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
    Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
    PLoS One, 9 (8), e103873
    DOI 10.1371/journal.pone.0103873, PubMed 25148029
  47. Winsel S, Mäki-Jouppila J, Tambe M, Aure MR, Pruikkonen S, Salmela AL, Halonen T, Leivonen SK, Kallio L, Børresen-Dale AL, Kallio MJ (2014)
    Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo
    Br J Cancer, 111 (11), 2142-51
    DOI 10.1038/bjc.2014.524, PubMed 25268374
  48. Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, Bessarabova M, Rueda OM, Nikolsky Y, Caldas C, Liu XS, Polyak K (2014)
    JARID1B is a luminal lineage-driving oncogene in breast cancer
    Cancer Cell, 25 (6), 762-77
    DOI 10.1016/j.ccr.2014.04.024, PubMed 24937458
  49. Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL (2014)
    Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
    BMC Cancer, 14, 211
    DOI 10.1186/1471-2407-14-211, PubMed 24645668

Publications 2013

  1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M et al. (2013)
    Signatures of mutational processes in human cancer
    Nature, 500 (7463), 415-21
    DOI 10.1038/nature12477, PubMed 23945592
  2. Andersen V, Vogel U, Godiksen S, Frenzel FB, Sæbø M, Hamfjord J, Kure E, Vogel LK (2013)
    Low ABCB1 gene expression is an early event in colorectal carcinogenesis
    PLoS One, 8 (8), e72119
    DOI 10.1371/journal.pone.0072119, PubMed 23977225
  3. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN (2013)
    Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
    Genome Biol, 14 (11), R126
    DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477
  4. Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
    Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
    PLoS One, 8 (1), e53014
    DOI 10.1371/journal.pone.0053014, PubMed 23382830
  5. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
    High levels of genomic aberrations in serous ovarian cancers are associated with better survival
    PLoS One, 8 (1), e54356
    DOI 10.1371/journal.pone.0054356, PubMed 23372714
  6. Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, Sauerwine BA, Shimoni Y, Moen Vollan HK, Mecham BH, Rueda OM, Tost J, Curtis C, Alvarez MJ, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Califano A, Friend SH, Ideker T, Schadt EE, Stolovitzky GA, Margolin AA (2013)
    Improving breast cancer survival analysis through competition-based multidimensional modeling
    PLoS Comput Biol, 9 (5), e1003047
    DOI 10.1371/journal.pcbi.1003047, PubMed 23671412
  7. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S et al. (2013)
    Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
    Nat Genet, 45 (4), 371-84, 384e1-2
    DOI 10.1038/ng.2566, PubMed 23535731
  8. Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
    Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
    Cell Stem Cell, 13 (1), 117-30
    DOI 10.1016/j.stem.2013.05.004, PubMed 23770079
  9. Edvardsen H, Landmark-Høyvik H, Reinertsen KV, Zhao X, Grenaker-Alnæs GI, Nebdal D, Syvänen AC, Rødningen O, Alsner J, Overgaard J, Borresen-Dale AL, Fosså SD, Kristensen VN (2013)
    SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling
    Int J Radiat Oncol Biol Phys, 86 (4), 791-9
    DOI 10.1016/j.ijrobp.2013.02.025, PubMed 23597419
  10. Engebraaten O, Vollan HKM, Børresen-Dale AL (2013)
    Triple-negative breast cancer and the need for new therapeutic targets
    Am J Pathol, 183 (4), 1064-1074
    DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
  11. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, Betts JA, Carroll T, Bailey PJ, Dicks E, Beesley J, Tyrer J, Maia AT, Beck A, Knoblauch NW, Chen C, Kraft P, Barnes D, González-Neira A, Alonso MR, Herrero D et al. (2013)
    Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
    Am J Hum Genet, 92 (4), 489-503
    DOI 10.1016/j.ajhg.2013.01.002, PubMed 23540573
  12. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J, Carpenter J, Godwin AK, Nevanlinna H, Giles GG, Cox A, Hopper JL, Bolla MK, Wang Q et al. (2013)
    Genome-wide association studies identify four ER negative-specific breast cancer risk loci
    Nat Genet, 45 (4), 392-8, 398e1-2
    DOI 10.1038/ng.2561, PubMed 23535733
  13. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V (2013)
    Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
    Cancer Res, 73 (21), 6424-34
    DOI 10.1158/0008-5472.CAN-12-4573, PubMed 24030979
  14. Holven KB, Retterstøl K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, Narverud I, Berge KE, Ose L, Aukrust P, Halvorsen B (2013)
    Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype
    PLoS One, 8 (11), e78241
    DOI 10.1371/journal.pone.0078241, PubMed 24244297
  15. Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M (2013)
    High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
    PLoS One, 8 (10), e77232
    DOI 10.1371/journal.pone.0077232, PubMed 24194875
  16. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS (2013)
    AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
    Breast Cancer Res Treat, 141 (3), 397-408
    DOI 10.1007/s10549-013-2702-z, PubMed 24091768
  17. Katika MR, Hurtado A (2013)
    A functional link between FOXA1 and breast cancer SNPs
    Breast Cancer Res, 15 (1), 303
    DOI 10.1186/bcr3360, PubMed 23427833
  18. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2013)
    Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
    Mol Oncol, 8 (1), 59-67
    DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443
  19. Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen-Dale AL, Tost J, Kristensen VN (2013)
    Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
    BMC Cancer, 13, 456
    DOI 10.1186/1471-2407-13-456, PubMed 24093668
  20. Kongsgaard A, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
    Clinical significance of disseminated tumour cells in non-small cell lung cancer
    Br J Cancer, 109 (5), 1264-70
    DOI 10.1038/bjc.2013.450, PubMed 23942067
  21. Kongsgaard A, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
    Osteopontin is a prognostic biomarker in non-small cell lung cancer
    BMC Cancer, 13, 540
    DOI 10.1186/1471-2407-13-540, PubMed 24215488
  22. Landmark-Høyvik H, Dumeaux V, Nebdal D, Lund E, Tost J, Kamatani Y, Renault V, Børresen-Dale AL, Kristensen V, Edvardsen H (2013)
    Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II
    Genomics, 102 (4), 278-87
    DOI 10.1016/j.ygeno.2013.07.006, PubMed 23880221
  23. Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M (2013)
    High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
    Mol Oncol, 8 (1), 93-104
    DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764
  24. Li J, Foo JN, Schoof N, Varghese JS, Fernandez-Navarro P, Gierach GL, Quek ST, Hartman M, Nord S, Kristensen VN, Pollán M, Figueroa JD, Thompson DJ, Li Y, Khor CC, Humphreys K, Liu J, Czene K, Hall P (2013)
    Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size
    J Med Genet, 50 (10), 666-73
    DOI 10.1136/jmedgenet-2013-101708, PubMed 23825393
  25. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
    Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
    Clin Cancer Res, 20 (2), 404-12
    DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
  26. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML (2013)
    Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer
    Breast Cancer Res Treat, 143 (1), 189-201
    DOI 10.1007/s10549-013-2796-3, PubMed 24305980
  27. Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J et al. (2013)
    Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
    Sci Transl Med, 5 (181), 181re1
    DOI 10.1126/scitranslmed.3006112, PubMed 23596205
  28. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 't Veer LJ, Hogervorst FB, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Lux MP et al. (2013)
    Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1
    Am J Hum Genet, 93 (6), 1046-60
    DOI 10.1016/j.ajhg.2013.10.026, PubMed 24290378
  29. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Breast and Ovarian Cancer Susceptibility Collaboration, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K et al. (2013)
    Large-scale genotyping identifies 41 new loci associated with breast cancer risk
    Nat Genet, 45 (4), 353-61, 361e1-2
    DOI 10.1038/ng.2563, PubMed 23535729
  30. Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, González-Neira A, Pita G, Alonso MR, Wang Q, Bolla MK, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Neuhausen SL, Ziogas A, Clarke CA, Hopper JL, Dite GS, Apicella C, Southey MC et al. (2013)
    A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
    Hum Mol Genet, 23 (7), 1934-46
    DOI 10.1093/hmg/ddt581, PubMed 24242184
  31. Myhre S, Lingjærde OC, Hennessy BT, Aure MR, Carey MS, Alsner J, Tramm T, Overgaard J, Mills GB, Børresen-Dale AL, Sørlie T (2013)
    Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins
    Mol Oncol, 7 (3), 704-18
    DOI 10.1016/j.molonc.2013.02.018, PubMed 23562353
  32. Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN (2013)
    Next-generation sequencing of disseminated tumor cells
    Front Oncol, 3, 320
    DOI 10.3389/fonc.2013.00320, PubMed 24427740
  33. Nilsen G, Borgan O, Liestøl K, Lingjærde OC (2013)
    Identifying clusters in genomics data by recursive partitioning
    Stat Appl Genet Mol Biol, 12 (5), 637-52
    DOI 10.1515/sagmb-2013-0016, PubMed 23942354
  34. Nordby T, Ikdahl T, Bowitz Lothe IM, Fagerland MW, Heiberg T, Hauge T, Labori KJ, Buanes T (2013)
    Improved survival and quality of life in patients undergoing R1 pancreatic resection compared to patients with locally advanced unresectable pancreatic adenocarcinoma
    Pancreatology, 13 (2), 180-5
    DOI 10.1016/j.pan.2013.01.003, PubMed 23561977
  35. Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland Å (2013)
    Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
    PLoS One, 8 (5), e62153
    DOI 10.1371/journal.pone.0062153, PubMed 23671585
  36. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA et al. (2013)
    Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
    Carcinogenesis, 35 (5), 1012-9
    DOI 10.1093/carcin/bgt404, PubMed 24325915
  37. Quigley DA, Fiorito E, Nord S, Van Loo P, Alnæs GG, Fleischer T, Tost J, Moen Vollan HK, Tramm T, Overgaard J, Bukholm IR, Hurtado A, Balmain A, Børresen-Dale AL, Kristensen V (2013)
    The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors
    Mol Oncol, 8 (2), 273-84
    DOI 10.1016/j.molonc.2013.11.008, PubMed 24388359
  38. Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS (2013)
    Two Distinct Categories of Focal Deletions in Cancer Genomes
    PLoS One, 8 (6), e66264
    DOI 10.1371/journal.pone.0066264, PubMed 23805207
  39. Riis ML, Zhao X, Kaveh F, Vollan HS, Nesbakken AJ, Solvang HK, Lüders T, Bukholm IR, Kristensen VN (2013)
    Gene expression profile analysis of t1 and t2 breast cancer reveals different activation pathways
    ISRN Oncol, 2013, 924971
    DOI 10.1155/2013/924971, PubMed 23533813
  40. Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
    Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
    Carcinogenesis, 35 (1), 76-85
    DOI 10.1093/carcin/bgt333, PubMed 24104550
  41. Tramm T, Hennig G, Kyndi M, Alsner J, Sørensen FB, Myhre S, Sørlie T, Overgaard J (2013)
    Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection
    Virchows Arch, 463 (6), 775-86
    DOI 10.1007/s00428-013-1486-1, PubMed 24100522
  42. Vangala RK, Ravindran V, Ghatge M, Shanker J, Arvind P, Bindu H, Shekar M, Rao VS (2013)
    Integrative bioinformatics analysis of genomic and proteomic approaches to understand the transcriptional regulatory program in coronary artery disease pathways
    PLoS One, 8 (2), e57193
    DOI 10.1371/journal.pone.0057193, PubMed 23468932
  43. Vangala RK, Ravindran V, Kamath K, Rao VS, Sridhara H (2013)
    Novel network biomarkers profile based coronary artery disease risk stratification in Asian Indians
    Adv Biomed Res, 2, 59
    DOI 10.4103/2277-9175.115805, PubMed 24223374
  44. Zhou W, Jirström K, Amini RM, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F (2013)
    Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study
    BMC Cancer, 13, 512
    DOI 10.1186/1471-2407-13-512, PubMed 24171825
  45. Zänker KS, Mihich E, Huber HP, Borresen-Dale AL (2013)
    Personalized cancer care conference
    J Pers Med, 3 (2), 70-81
    DOI 10.3390/jpm3020070, PubMed 25562519

Publications 2012

  1. Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S (2012)
    Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers
    PLoS One, 7 (6), e38575
    DOI 10.1371/journal.pone.0038575, PubMed 22719901
  2. Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
    Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
    Mol Oncol, 7 (1), 130-42
    DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
  3. Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
    [Mutation testing for non-small-cell lung cancer]
    Tidsskr Nor Laegeforen, 132 (8), 952-5
    DOI 10.4045/tidsskr.11.1017, PubMed 22562326
  4. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L et al. (2012)
    The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    Nature, 486 (7403), 346-52
    DOI 10.1038/nature10983, PubMed 22522925
  5. Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
    Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
    ISRN Oncol, 2012, 176789
    DOI 10.5402/2012/176789, PubMed 22666610
  6. Fiorito E, Katika MR, Hurtado A (2012)
    Cooperating transcription factors mediate the function of estrogen receptor
    Chromosoma, 122 (1-2), 1-12
    DOI 10.1007/s00412-012-0392-7, PubMed 23192763
  7. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale AL, Levine AJ, Bargonetti J, Prives C (2012)
    Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
    Cell, 148 (1-2), 244-58
    DOI 10.1016/j.cell.2011.12.017, PubMed 22265415
  8. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C, Baynes C, Conroy D, Maranian M, Ahmed S, Driver K, Johnson N, Orr N, dos Santos Silva I, Waisfisz Q, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON), Hall P, Czene K et al. (2012)
    Genome-wide association analysis identifies three new breast cancer susceptibility loci
    Nat Genet, 44 (3), 312-8
    DOI 10.1038/ng.1049, PubMed 22267197
  9. Gilfillan S, Fiorito E, Hurtado A (2012)
    Functional genomic methods to study estrogen receptor activity
    J Mammary Gland Biol Neoplasia, 17 (2), 147-53
    DOI 10.1007/s10911-012-9254-4, PubMed 22588661
  10. Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS (2012)
    Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
    Ann Oncol, 23 (12), 2997-3006
    DOI 10.1093/annonc/mds586, PubMed 23166150
  11. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
    Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
    PLoS One, 7 (4), e34150
    DOI 10.1371/journal.pone.0034150, PubMed 22529906
  12. Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ, Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquita HB, Muir KR, Lophatananon A, Rattanamongkongul S, Puttawibul P, Fasching PA, Hein A, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Sawyer E, Tomlinson I, Kerin M et al. (2012)
    Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
    PLoS One, 7 (8), e42380
    DOI 10.1371/journal.pone.0042380, PubMed 22879957
  13. Jamaly S, Khanehkenari MR, Rao R, Patil G, Thakur S, Ramaswamy P, Ajaikumar BS, Sahoo R (2012)
    Relationship between p53 overexpression, human papillomavirus infection, and lifestyle in Indian patients with head and neck cancers
    Tumour Biol, 33 (2), 543-50
    DOI 10.1007/s13277-011-0295-x, PubMed 22231431
  14. Joshi H, Bhanot G, Børresen-Dale AL, Kristensen V (2012)
    Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
    Br J Cancer, 107 (10), 1722-8
    DOI 10.1038/bjc.2012.461, PubMed 23079576
  15. Joshi H, Nord SH, Frigessi A, Børresen-Dale AL, Kristensen VN (2012)
    Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes
    BMC Genomics, 13, 199
    DOI 10.1186/1471-2164-13-199, PubMed 22616941
  16. Kim J, Villadsen R, Sørlie T, Fogh L, Grønlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H, Edwards PA, Børresen-Dale AL, Rønnov-Jessen L, Bissell MJ, Petersen OW (2012)
    Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity
    Proc Natl Acad Sci U S A, 109 (16), 6124-9
    DOI 10.1073/pnas.1203203109, PubMed 22454501
  17. Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
    Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    BMC Cancer, 12, 534
    DOI 10.1186/1471-2407-12-534, PubMed 23167843
  18. Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T (2012)
    KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
    Expert Rev Mol Diagn, 12 (4), 327-8
    DOI 10.1586/erm.12.29, PubMed 22616697
  19. Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, Dite GS, Apicella C, Southey MC, Schmidt MK, Broeks A, Cornelissen S, van Hien R, Sawyer E, Tomlinson I, Kerin M, Miller N, Milne RL, Zamora MP, Pérez JI, Benítez J, Hamann U, Ko YD, Brüning T, GENICA Network et al. (2012)
    11q13 is a susceptibility locus for hormone receptor positive breast cancer
    Hum Mutat, 33 (7), 1123-32
    DOI 10.1002/humu.22089, PubMed 22461340
  20. Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
    Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
    Breast Cancer Res, 14 (4), R117
    DOI 10.1186/bcr3242, PubMed 22889108
  21. Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS (2012)
    Functional characterization of the 19q12 amplicon in grade III breast cancers
    Breast Cancer Res, 14 (2), R53
    DOI 10.1186/bcr3154, PubMed 22433433
  22. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J et al. (2012)
    Mutational processes molding the genomes of 21 breast cancers
    Cell, 149 (5), 979-93
    DOI 10.1016/j.cell.2012.04.024, PubMed 22608084
  23. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR et al. (2012)
    The life history of 21 breast cancers
    Cell, 149 (5), 994-1007
    DOI 10.1016/j.cell.2012.04.023, PubMed 22608083
  24. Nilsen G, Liestøl K, Van Loo P, Moen Vollan HK, Eide MB, Rueda OM, Chin SF, Russell R, Baumbusch LO, Caldas C, Børresen-Dale AL, Lingjaerde OC (2012)
    Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
    BMC Genomics, 13, 591
    DOI 10.1186/1471-2164-13-591, PubMed 23442169
  25. Otto B, Gruner K, Heinlein C, Wegwitz F, Nollau P, Ylstra B, Pantel K, Schumacher U, Baumbusch LO, Martin-Subero JI, Siebert R, Wagener C, Streichert T, Deppert W, Tolstonog GV (2012)
    Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression
    Int J Cancer, 132 (6), 1300-10
    DOI 10.1002/ijc.27783, PubMed 22907219
  26. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
    Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
    PLoS One, 7 (11), e50806
    DOI 10.1371/journal.pone.0050806, PubMed 23226389
  27. Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR (2012)
    Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
    ISRN Oncol, 2012, 450267
    DOI 10.5402/2012/450267, PubMed 23227362
  28. Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT (2012)
    Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
    J Thorac Oncol, 7 (1), 57-63
    DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838
  29. Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O (2012)
    The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
    Mol Oncol, 7 (3), 392-401
    DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899
  30. Shanker J, Rao VS, Ravindran V, Dhanalakshmi B, Hebbagodi S, Kakkar VV (2012)
    Relationship of adiponectin and leptin to coronary artery disease, classical cardiovascular risk factors and atherothrombotic biomarkers in the IARS cohort
    Thromb Haemost, 108 (4), 769-80
    DOI 10.1160/TH12-04-0263, PubMed 22955445
  31. Stavnes HT, Nymoen DA, Langerød A, Holth A, Børresen Dale AL, Davidson B (2012)
    AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
    Virchows Arch, 462 (2), 163-73
    DOI 10.1007/s00428-012-1347-3, PubMed 23242172
  32. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A et al. (2012)
    The landscape of cancer genes and mutational processes in breast cancer
    Nature, 486 (7403), 400-4
    DOI 10.1038/nature11017, PubMed 22722201
  33. Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H, GENICA Network, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C et al. (2012)
    19p13.1 is a triple-negative-specific breast cancer susceptibility locus
    Cancer Res, 72 (7), 1795-803
    DOI 10.1158/0008-5472.CAN-11-3364, PubMed 22331459
  34. Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
    Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
    Acta Oncol, 52 (1), 91-101
    DOI 10.3109/0284186X.2012.713508, PubMed 22934555
  35. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
    Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    J Clin Oncol, 30 (15), 1755-62
    DOI 10.1200/JCO.2011.38.0915, PubMed 22473155
  36. Vachon CM, Scott CG, Fasching PA, Hall P, Tamimi RM, Li J, Stone J, Apicella C, Odefrey F, Gierach GL, Jud SM, Heusinger K, Beckmann MW, Pollan M, Fernández-Navarro P, Gonzalez-Neira A, Benitez J, van Gils CH, Lokate M, Onland-Moret NC, Peeters PH, Brown J, Leyland J, Varghese JS, Easton DF et al. (2012)
    Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk
    Cancer Epidemiol Biomarkers Prev, 21 (7), 1156-66
    DOI 10.1158/1055-9965.EPI-12-0066, PubMed 22454379
  37. Vaclavikova R, Ehrlichova M, Hlavata I, Pecha V, Kozevnikovova R, Trnkova M, Adamek J, Edvardsen H, Kristensen VN, Gut I, Soucek P (2012)
    Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis
    Clin Chem Lab Med, 50 (11), 1999-2007
    DOI 10.1515/cclm-2012-0103, PubMed 23093106
  38. Van Loo P, Nilsen G, Nordgard SH, Vollan HK, Børresen-Dale AL, Kristensen VN, Lingjærde OC (2012)
    Analyzing cancer samples with SNP arrays
    Methods Mol Biol, 802, 57-72
    DOI 10.1007/978-1-61779-400-1_4, PubMed 22130873
  39. Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van't Veer LJ, Garcia-Closas M, Hopper JL, Hall P, Andrulis IL, Devilee P, Fasching PA, Anton-Culver H, Lambrechts D, Hooning M, Cox A, Giles GG, Burwinkel B, Lindblom A, Couch FJ, Mannermaa A, Grenaker Alnæs G, John EM, Dörk T, Flyger H et al. (2012)
    CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer
    J Clin Oncol, 30 (35), 4308-16
    DOI 10.1200/JCO.2012.42.7336, PubMed 23109706

Publications 2011

  1. Borgan E, Navon R, Vollan HK, Schlichting E, Sauer T, Yakhini Z, Lingjærde OC, Sørlie T, Børresen-Dale AL (2011)
    Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue
    Mol Oncol, 5 (6), 564-76
    DOI 10.1016/j.molonc.2011.08.004, PubMed 21917534
  2. Borge KS, Børresen-Dale AL, Lingaas F (2011)
    Identification of genetic variation in 11 candidate genes of canine mammary tumour
    Vet Comp Oncol, 9 (4), 241-50
    DOI 10.1111/j.1476-5829.2010.00250.x, PubMed 22077404
  3. Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK (2011)
    The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
    BMC Cancer, 11, 65
    DOI 10.1186/1471-2407-11-65, PubMed 21310043
  4. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C et al. (2011)
    Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
    Hum Mol Genet, 20 (16), 3289-303
    DOI 10.1093/hmg/ddr228, PubMed 21596841
  5. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O (2011)
    Identification of fusion genes in breast cancer by paired-end RNA-sequencing
    Genome Biol, 12 (1), R6
    DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443
  6. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
    miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
    PLoS One, 6 (2), e16915
    DOI 10.1371/journal.pone.0016915, PubMed 21364938
  7. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB (2011)
    Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Clin Proteomics, 8 (1), 11
    DOI 10.1186/1559-0275-8-11, PubMed 21906370
  8. Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS (2011)
    13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
    NMR Biomed, 24 (10), 1243-52
    DOI 10.1002/nbm.1683, PubMed 21462378
  9. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
    Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
    Cancer Discov, 1 (1), 78-89
    DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973
  10. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
    Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
    PLoS One, 6 (4), e18064
    DOI 10.1371/journal.pone.0018064, PubMed 21533284
  11. Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
    EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
    J Thorac Oncol, 6 (5), 947-50
    DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
  12. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang Y, Kong B, Langerød A, Børresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY (2011)
    Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters
    Nat Genet, 43 (7), 621-9
    DOI 10.1038/ng.848, PubMed 21642992
  13. Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
    Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
    BMC Cancer, 11, 332
    DOI 10.1186/1471-2407-11-332, PubMed 21812955
  14. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
    Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
    BMC Med Genomics, 4, 77
    DOI 10.1186/1755-8794-4-77, PubMed 22044755
  15. Kaveh F, Edvardsen H, Børresen-Dale AL, N Kristensen V, Solvang HK (2011)
    Allele-specific disparity in breast cancer
    BMC Med Genomics, 4, 85
    DOI 10.1186/1755-8794-4-85, PubMed 22188678
  16. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
  17. Kristensen VN (2011)
    Divide and conquer: the genetic basis of molecular subclassification of breast cancer
    EMBO Mol Med, 3 (4), 183-5
    DOI 10.1002/emmm.201100128, PubMed 21394915
  18. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
    Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
    Proc Natl Acad Sci U S A, 109 (8), 2802-7
    DOI 10.1073/pnas.1108781108, PubMed 21908711
  19. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA (2011)
    ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues
    Front Biosci (Elite Ed), 3 (4), 1443-55
    DOI 10.2741/e345, PubMed 21622148
  20. Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2011)
    High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
    Int J Cancer, 131 (4), E405-15
    DOI 10.1002/ijc.26444, PubMed 21935921
  21. Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Pérez JI, Benítez J, Dörk T, Schürmann P, Karstens JH, Hillemanns P, Cox A, Brock IW, Elliot G, Cross SS, Seal S, Turnbull C, Renwick A, Rahman N, Shen CY, Yu JC et al. (2011)
    Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer
    Cancer Epidemiol Biomarkers Prev, 20 (10), 2222-31
    DOI 10.1158/1055-9965.EPI-11-0569, PubMed 21795498
  22. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
    The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
    Breast Cancer Res, 13 (3), R61
    DOI 10.1186/bcr2898, PubMed 21672237
  23. Møller P, Clark N, Mæhle L (2011)
    A SImplified method for Segregation Analysis (SISA) to determine penetrance and expression of a genetic variant in a family
    Hum Mutat,